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Thesis overview & structure 
 
This thesis portfolio is comprised of two separate chapters: the first, a systematic literature 
review and the second, an empirical research project. The aim of the systematic review was to 
explore the prevalence of prenatal alcohol exposure as assessing using meconium biomarkers 
in general maternity populations. The focus of the empirical study was to explore prenatal 
alcohol use in the UK and the impact of an educational intervention on women’s knowledge 
and attitudes, using a quantitative approach.   
 
Both sections adhere to submission guidelines for the BMC Pregnancy and Childbirth Journal. 
Additional information for the systematic review and empirical study is presented within the 
references and appendix section of each chapter, which immediately follows the main text.   
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Alcohol is a well-known teratogen and its consumption during pregnancy is a growing public 
health concern across the globe. Prevalence rates of prenatal alcohol use remain high, despite 
international guidelines recommending abstinence. This has significant consequences as it is a 
direct cause of foetal alcohol spectrum disorder, which is known to have widespread adverse 
effects on the individual, their families and wider society. Ascertaining the true extent of 




The purpose of the systematic review was to assess the international prevalence of prenatal 
alcohol exposure as obtained using meconium biomarkers in general maternity populations.  
The purpose of the empirical study was to explore the prevalence of prenatal alcohol use by 
self-report of women in the UK, and the impact of an educational intervention on attitudes and 
knowledge towards drinking during pregnancy.   
 
Methodology 
The systematic review was completed on studies reporting the prevalence of prenatal alcohol 
exposure as determined by meconium biomarker testing, and their methodological quality was 
appraised. A national anonymous online study was conducted for the empirical study. This 
comprised of an educational intervention and questionnaire measures assessing prevalence of 
self-report prenatal alcohol use, attitudes and knowledge.  
 
Results 
Findings from the systematic review demonstrated that prevalence rates of prenatal alcohol 
exposure assessed using meconium biomarkers varied from 2.4% to 44%. Studies were found 
to be of moderate quality, although varied greatly with respect to their sociodemographic and 
methodological characteristics. Findings from the empirical study demonstrated high rates of 
binge drinking prior to pregnancy (82%), which decreased significantly following recognition 
of pregnancy (0.2%). The educational intervention was found to have a significant impact on 




Results of the systematic review support the utility of meconium as a promising objective tool 
for the detection of prenatal alcohol exposure but recommends use with caution and adherence 
to stringent methodological protocols. Further research is warranted on its utility in clinical 
practice. Results of the empirical study support the use of educational interventions in 
improving women’s knowledge of risks and increasing negative attitudes towards prenatal 
alcohol use. Recommendations for implementation of such interventions at community and 
clinical levels to reduce prenatal alcohol use and subsequent risks of foetal alcohol spectrum 
disorder are made.   
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Lay summary  
 
Background 
Drinking alcohol during pregnancy can cause long-term harm to the baby and, can lead to a 
range of deficits known as Foetal Alcohol Spectrum Disorder (FASD). The message from 
international health bodies such as the World Health Organisation and the UK’s Chief Medical 
Officers is that the safest approach for pregnant women is to not drink alcohol at all. This 
guidance has changed overtime however and there has been conflicting advice as to whether 
or not small amounts of alcohol during pregnancy are harmful. This has led to different 
attitudes and beliefs amongst the general public healthcare professionals and despite the known 
risks, drinking during pregnancy remains a significant and growing public health concern 
across the globe today.  
 
It is difficult to get a clear picture on how prevalent alcohol consumption during pregnancy is 
in society, and there has been different ways used to assess this in order for the baby and its 
mother to best be supported. One way to detect alcohol use in pregnancy is by analysing the 
first stool a baby passes after birth, which is known as the meconium. Alcohol and drugs 
consumed in the second and third trimesters of pregnancy are metabolised in the foetus and 
stored in this meconium. Meconium can be collected after birth and tested in a lab to indicate 
if the baby was exposed to alcohol. Positive meconium tests indicate heavier levels of drinking 
in the later stages of pregnancy. A second way to obtain information on alcohol use during 
pregnancy is through self-report. This is when women are asked about their alcohol intake by 
their healthcare professional, and can be done through discussion or by using questionnaires. 
Gathering this information is crucial for detecting babies who might be at risk of FASD, and 
mothers at risk of alcohol-related harm, as without it babies often go unsupported, undiagnosed, 
and the right treatment cannot be given.  
 
Preventing and reducing alcohol use in pregnancy is crucial, and this is a major focus of public 
health interventions such as media campaigns and education interventions. These help to 
educate the general public of the risks associated with drinking in pregnancy.  
 
Objectives  
This thesis is made up of two chapters; the first is a systematic review and the second is a 
research study. The aim of the systematic review was to investigate all of the studies carried 
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out between 1990 and January 2021 which reported the prevalence of alcohol exposure during 
pregnancy by using meconium testing. It summarises results from 12 studies which included 
women who gave birth in general maternity settings. The purpose was to find out whether the 
research can indicate how common alcohol use in pregnancy is by using these tests. It also 
looked at the quality of the studies done and aimed to help make recommendations for how 
useful these tests might be in clinical practice.  
 
The aim of the research study was to assess drinking during pregnancy in women in the UK by 
using an online self-report questionnaire. This is an emotive topic and there is a lot of social 
stigma attached to it, and because of this, this study was done anonymously in the hope of 
gathering more accurate information. A further aim of this study was to explore women’s 
attitudes and knowledge towards drinking during pregnancy in the UK and how an information 
leaflet might have an impact on these. This study wanted to know how women in the UK felt 
about the guidance to abstain from drinking during pregnancy and how knowledgeable they 
were about the risks.  
 
Results  
Results of the systematic review found that the rate of babies exposed to alcohol in second and 
third trimester of pregnancy varied widely between the studies, from 2.4% to 44%. Studies 
were from different countries around the world and were quite different in the samples of 
women they recruited, and the way meconium was collected, stored and tested. It was not 
feasible to group studies together to get an indication of the prevalence worldwide, however 
findings did suggest that meconium testing could be helpful for detecting drinking in 
pregnancy.  
 
Over 1,500 women in the UK took part in the online research study from July to December 
2020. Results found that the majority (82%) of women were drinking heavily before they found 
out they were pregnant, although this decreased significantly after they found out. Still, 25% 
of women reported drinking during their pregnancy after they had found out. The impact of the 
information leaflet was significant, as after reading this, women were more strongly opposed 
to drinking in pregnancy and were more knowledgeable about the risks associated with 





Findings of the review were helpful as they demonstrated that meconium testing is a useful and 
objective way of gathering information on alcohol exposure, however more research is needed 
before using such tests routinely in clinical practice. The research study demonstrated that 25% 
of women continued to drink during pregnancy, and the information leaflet was helpful in 
changing women’s attitudes towards drinking and improving their knowledge of the risks. This 
is important as the risks of drinking are high, and by raising awareness and informing women 
of the risks we can help to reduce drinking during pregnancy. This in turn would help to 
decrease the rate of FASD and alcohol-related harm to mother and baby, as well as reduce the 
burden of this on individuals, their families and on healthcare systems. Recommendations to 



























List of abbreviations  
 
 
Abbreviation  Explanation  
PAE Prenatal Alcohol Exposure  
PAU Prenatal Alcohol Use  
FAS Foetal Alcohol Syndrome 
FASD Foetal Alcohol Spectrum Disorder  
FAEE Fatty Acid Ethyl Ester 
EtG Ethyl Glucuronide  
EtS Ethyl Sulfate 




Chapter 1: Systematic Review 
 
The international prevalence of prenatal alcohol exposure obtained 




Orlagh Keatingab, Dr Renate Kuenssbergb, Sarah Driscollab, Dr Suzanne O’Rourkea 
 
a Clinical and Health Psychology Department, University of Edinburgh, UK 
b NHS Fife Psychology Department, Lynebank Hospital, Dunfermline, UK 
 
 
Corresponding Author:  
Orlagh Keating 








1 Written in accordance with submission guidelines for the BMC Pregnancy & Childbirth 
Journal (See Appendix A) 
 









Background: Alcohol is a well-known teratogen and its consumption during pregnancy is a 
growing public health concern across the globe. Ascertaining the true extent of this remains a 
major challenge however as maternal self-reports may lack validity. Objective measures have 
gained increasing attention over recent years and meconium is recognised as a valuable tool to 
detect prenatal alcohol exposure. This review assesses the international prevalence of PAE as 
obtained using meconium biomarkers in general maternity populations.   
 
Methods: A comprehensive search of the literature for studies reporting the prevalence of 
prenatal alcohol exposure as determined by meconium biomarker testing was conducted using 
multiple electronic databases from 1990 to February 2021. Twelve studies were identified for 
inclusion and evaluated for methodological quality. 
 
Results: The prevalence of PAE as measured using FAEE meconium biomarkers varied widely 
from 2.4% to 44%. Rates based on EtG analysis ranged from 2.9% to 15%, and EtS analysis 
from 7.8% to 16.7%. Studies were of moderate quality, although high heterogeneity was 
observed. Prevalence rates based on self-report data ranged from 0.5% to 37%.  
 
Conclusions: Large variations in prevalence rates reflected the diverse nature of the individual 
studies and differences in sociodemographic and methodological characteristics.  Meconium 
appears to be a promising objective tool for the detection of PAE but requires methodological 
rigour and adherence to stringent protocols for sample collection, storage and analysis.  Caution 
should be used when interpreting prevalence rates based on meconium screening, and further 
research is warranted to develop consistent guidance on the ascertainment, analysis and 
reporting of meconium samples.Furthermore, the ethical challenges of meconium screening 
should be considered due to the significant impact these have on public health advice. 
Implications for clinical practice and recommendations for public policy are discussed.  
Keywords 







Prenatal alcohol consumption  
Alcohol consumption is a part of the social landscape for many societies; however, it 
is also a significant global health concern, and harmful use is accountable for 5.1% of the global 
burden of disease (World Health Organisation [WHO], 2018). Prevalence rates have markedly 
increased between the years 1990 and 2017, particularly in lower- and middle-income countries 
including India, China and Vietnam (Manthey et al., 2019), although the heaviest rate of 
drinking is currently observed in Europe (WHO, 2018). Contributing factors to this in Western 
Europe include greater social acceptance around alcohol use and minimisation of the associated 
risks. The epidemiology of alcohol use has also changed and there has been a generational 
increase in consumption among younger cohorts of both men and women (Slade et al., 2016). 
 
Of particular concern is the level of alcohol consumption in women of reproductive age 
and more specifically during pregnancy, otherwise known as prenatal alcohol use (PAU). 
2019). Alcohol is a well-established teratogen, and its consumption during pregnancy places 
the foetus at risk of congenital malformations and birth defects. Prenatal alcohol exposure 
(PAE) increases risks of low birth weight, miscarriage, preterm births and perinatal mortality, 
and is the direct cause of Foetal Alcohol Spectrum Disorder (FASD) (NIAAA, 2021); an 
umbrella term for a range of cognitive, behavioural and neurodevelopmental deficits observed 
as a result of PAE. Alarmingly, PAU is a relatively common and socially pervasive behaviour 
despite public health initiatives to reduce and eliminate PAU, and widespread 
recommendations in many countries for women to abstain from alcohol during pregnancy. 
 
Prevalence of PAU and FASD varies across the globe. One systematic review 
conducted by Popova et al. (2017) estimated that the global prevalence of Fetal Alcohol 
Syndrome (FAS; the most severe form of FASD) in the general population was 14.6 per 10,000 
individuals. The authors found the global prevalence estimate of PAU to be approximately 
10%, with one in every 67 of these babies exposed to alcohol having FAS. They also 
demonstrated that Europe has the highest prevalence of FAS as one quarter of women drink 
during pregnancy. High prevalence equates to high costs, and the economic consequences are 
substantial, with annual costs of a child with FASD estimated at $22,810, and an overall 
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estimated cost of over £2 billion in the UK per year (National Institute for Health and Care 
Excellence [NICE], 2019).  
 
However, these existing estimates are likely to be an under-representation of the full 
economic burden on individuals with FASD, their caregivers, and society (Greenmyer et al., 
2018). FASD presents as a wide range of manifestations, from more subtle impairments to 
severe developmental delays, and can profoundly impact on a person’s functional ability within 
society (Bryanton et al., 2014). There is a high burden on the individual and their caregivers, 
as those with FASD are likely to have significant additional needs requiring long-term support 
(Popova et al., 2011). Extensive literature on the long-term impact of PAE demonstrates that 
individuals are at a greatly increased risk for numerous secondary adverse outcomes including 
mental health problems (O’Connor & Paley, 2009), disrupted school experiences, law 
violations, substance misuse problems, confinement and inappropriate sexual behaviour 
(Streissguth et al., 2004). Therefore, it is not surprising that providing care for a child with 
FASD has unique challenges, and studies have indicated high levels of caregiver stress (Bobbitt 
et al., 2016), isolation, and a perceived lack of support (Mukherjee et al., 2013).  
 
Early identification of PAU, diagnosis of FASD and timely implementation of 
interventions are all protective factors against such adverse outcomes (McLachlan et al., 2015). 
However, there appears to be a ‘diagnostic dilemma’, as PAU and the associated effects are 
difficult to identify, diagnose and treat (Brown et al., 2011). Research on the epidemiology of 
PAU and FASD is constrained by the different methodology and diagnostic criteria used 
(Andrew, 2011), and as a result prevalence and incidence data on PAU and FASD is not well 
understood.  
 
Screening and assessment of PAU 
Research has continued to explore various methods of ascertaining information on PAU 
in order to assess the true extent of this, and subsequent prevalence of FASD. The reference 
standard for identifying PAU is maternal self-report. These subjective measures obtain 
maternal history and information on PAU through discussion between the mother and 
healthcare professional, and/or by use of alcohol screening questionnaires such as: 
AUDIT/AUDIT-C (Saunders et al., 1993; Bush et al.,1998), T-ACE (Sokol et al., 1989), 
CAGE (Mayfield et al., 1974) and TWEAK (Russell & Bigler, 1979), to name but a few. 
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However, prevalence based on maternal self-report is problematic due to the high probability 
of error, as factors likely to impact accuracy include the potential for socially desirable 
responding and recall bias, as well as accidental or intentional underreporting. Research has 
continuously demonstrated that pregnant women commonly underreport alcohol use (Ernhart 
et al., 1998; Derauf et al., 2003) and, based on alcohol sales data, this gap could be as much as 
40% (Boniface and Shelton, 2013). Lack of understanding of alcohol unit measures and drink 
strength, and shame and stigma associated with PAU are likely contributing factors to 
underreporting of PAU. This poses significant challenges when determining prevalence as well 
as establishing risks to the unborn baby, making clinical diagnoses of FASD, and implementing 
treatment plans.  
 
Objective methods have been explored in order to ascertain more accurate prevalence 
data, and the focus of research over recent years has been to identify and quantify metabolites 
of alcohol for use in diagnostic and prediction tools (Papaseit et al., 2019). As such, alcohol 
biomarkers have received growing attention (McQuire et al., 2016). Alcohol metabolites can 
be detected in a range of biological matrices from the mother (blood, hair, urine, plasma, sweat, 
oral fluid), newborn (meconium, urine, hair, blood) and from the fetal-maternal exchange 
(placenta, amniotic fluid and umbilical cord) (Concheiro et al., 2017). With the exception of 
amniotic fluid, these matrices are advantageous as their collection is non-invasive and can 
detect prenatal alcohol exposure (PAE) at different gestational periods (Lozano et al., 2007). 
Amongst these, meconium has been considered the ‘gold standard’ to detect alcohol and drug 
exposure in utero (Concheiro-Guisan & Concheiro, 2014). 
 
Metabolites of alcohol and meconium 
Meconium is the first stool the newborn passes within 72 hours after birth. Direct 
metabolites of alcohol can be found within the meconium of newborns as a result of maternal 
drinking. Meconium starts to form around week 12 of gestation and accumulates during 
pregnancy until birth, thereby serving as a reservoir of exposure to alcohol and drugs during 
second and third trimesters. The last trimester (weeks 28-40) in particular produces 75% of 
meconium (Bakdash et al., 2010). Alcohol goes through oxidative and non-oxidative metabolic 
processes to produce fatty acid ethyl esters (FAEEs), ethyl glucuronide (EtG) and ethyl sulfate 
(EtS) (as illustrated in Figure 1). These are then stored for longer periods than the alcohol itself 





Figure 1  
 
Illustration from Papaseit et al. (2019) on the Process of Alcohol Metabolism during 
Pregnancy and Meconium Biomarkers (used with permission) 
 
 
Note. This article was published in “Neuroscience of Alcohol: Mechanisms and Treatment”, Chapter 
60, Papaseit, E., Muga, R., Zuluaga, P., Sanvisens, A., & Farré, M. Meconium Biomarkers of Prenatal 
Alcohol Exposure, page 587, Copyright Elsevier (2019) 
 
 
Meconium biomarkers do not cross the placenta and therefore represent alcohol 
metabolised within the foetus (Goh et al., 2010). High levels of FAEE’s have been documented 
in the meconium of babies of women who drank heavily during pregnancy (Bearer et al., 2003, 
Chan et al., 2003). Research has illustrated that meconium FAEE analysis has a fivefold 
increase in sensitivity over self-report methods (Gareri et al., 2008) and has demonstrated 
100% sensitivity and 98% specificity when a cumulative cut-off of 2.0 nmol/g is used (Chan 
et al., 2003). EtG and EtS have also been identified as valid biological markers, although there 
are less published reports on these in comparison to FAEE (Himes et al., 2015). Research has 
shown that concentrations of EtG >30ng/g have high rates of sensitivity and specificity in 
identifying regular PAU (82% and 75%, respectively) and has shown moderate correlation to 
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self-reported PAU (k = 0.57, 95% CI 0.4 – 0.7) (Himes et al., 2015). Meconium EtS is less 
well-established as a marker of PAU compared to EtG, although is considered a useful 
biomarker (Bager et al., 2017). A review conducted on the diagnostic accuracy of biomarkers 
concluded that meconium screening is a promising tool for detecting PAE, although further 
larger scale research on population samples is still required (McQuire et al., 2016). 
Nevertheless, meconium is an easily obtainable non-invasive neonatal screening tool for 
identifying PAE and biomarkers have been shown to provide more accurate data than maternal 
self-reports/questionnaires (Papaseit et al., 2019). 
 
Rationale & research questions  
Obtaining reliable information on PAU is challenging as methods to detect PAE are 
constrained by a multitude of factors. Predominantly research has focused on the utility of 
maternal self-reports for identifying infants at risk of alcohol exposure, however they are 
limited by reporting and recall bias and likely to result in an underestimation of prevalence 
rates for PAU and FASD. Objective measures such as meconium biomarkers may prove more 
accurate in determining prevalence of PAE. One previous systematic review compared the 
prevalence of PAU via meconium and maternal self-reports (Lange et al., 2014), however it 
included studies that recruited from high-risk antenatal settings such as neonatal intensive care 
units (Pichini et al., 2009; Manich et al., 2011) and high-risk obstetric units (Goh et al., 2010). 
Research has demonstrated that infants born in high-risk settings are at greater risk of screening 
positive for PAE (Goh et al., 2010), thus potentially compromising the generalisability of 
findings. 
 
 The objective of this review was to identify the prevalence of PAE as obtained using 
meconium biomarkers of alcohol including FAEEs, EtG & EtS in general maternity settings. 
Additionally, a major focus of governments and public health bodies globally over recent years 
has been on the prevention and identification of PAE in order to facilitate diagnosis of FASD 
and implement interventions. More research exploring the utility of meconium biomarkers as 
a valid method of assessing PAE has been published over recent years, and this review aims to 
update the literature on prevalence with the hope of informing policy and recommendations for 
its utility.  
 
The following research questions were addressed: 
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1. What is the international prevalence of PAE in representative maternity populations as 
indicated by meconium biomarkers? 
2. What is the prevalence of PAE as indicated by meconium FAEE’s, EtG and EtS 
biomarkers independently? 

















This systematic review was conducted in accordance with Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses standards (PRISMA; Moher et al., 2009), and 
adhered to the principles recommended by the Centre for Reviews and Dissemination (CRD, 
2009). Prior to formal screening a protocol was registered on PROSPERO international 
prospective register of systematic reviews and is available at 
https://www.crd.york.ac.uk/prospero/ (record number: CRD42021229732).  
 
Information sources and search strategy  
A literature search was conducted to identify published and unpublished studies that 
investigated the prevalence of prenatal alcohol exposure in general maternal populations using 
meconium biomarkers. Scoping searches were initially conducted between December 11th 
2020 and January 17th 2021, and the final search was conducted on February 10th 2021. The 
following electronic bibliographic databases were searched: APA PsycInfo, Embase 
Classic+Embase, Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-
Indexed Citations and Daily, ProQuest Dissertations and Thesis Global, Cumulative Index to 
Nursing and Allied Health Literature (CINAHL Plus), Scopus and OpenGrey. References of 
included full-text studies were examined for additional relevant literature. Searches were 
limited to English language publications published since 1990, and animal studies were 
excluded.  
 
The search was conducted utilising numerous combinations of the following key words: 
1) Prevalen*, epidemiolog*, frequenc*, occur*, inciden*, probability, rate* OR statistic*; 
AND 2) Prenatal, pregnan*, antenat*, postnat*, primigravida, expect* mother*, matern*, 
maternal-fetal exchange, infant, newborn*, baby; AND 3) Alcohol*, ethanol, binge drinking, 
ARBD, ARND, drunk*, FAS, FASD, Intoxicat*, PAE OR pFAS; AND 4) meconium, FAEE, 
"alcohol metabolite*", "fatty acid* ethyl ester*", EtG, "ethyl glucuronide*", “ethyl sulfate” OR 
EtS (see Appendix B for terms utilised for each database).  
 
If published abstracts were deemed relevant but full texts of the studies were not yet 
published/available, authors of studies were contacted to provide additional information to 
include within the analysis. A specified time limit of four weeks was given for authors to 
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respond. Studies were excluded on the basis of lack of specified criteria if no further 
information was provided.  
 
Eligibility criteria  
Articles were retained if the following inclusion criteria were met: (i) observational 
study designs including retrospective and prospective cohort studies and cross-sectional 
studies; (ii) original and quantitative in nature and published in a peer-reviewed or scholarly 
report; (iii) report an estimated prevalence of prenatal alcohol exposure or report results which 
allow for its calculation; (iv) prevalence must have been measured by meconium biomarkers; 
(v) Population of pregnant/post-partum women and/or neonates in general maternity settings.   
 
Articles were excluded if they were: 
(i) Animal studies, individual case studies, and studies which did not provide data to assess 
primary outcomes, or which included secondary analysis of data; (ii) Review studies or meta-
analyses; (iii) Studies reporting a pooled estimate of PAE by combining several studies; (iv) 
specific populations not representative of the general population, such as substance use 
populations, neonates born in high-risk obstetric/antenatal units (v) Studies published in 
iteration i.e., if papers were subsequent publications of results already included.  
 
Study selection  
Following de-duplication of the studies returned from the searches, titles and abstracts 
were screened for eligibility by the first and third author. For abstracts and publications deemed 
relevant, full texts were retrieved or requested. Additionally, for studies where the title and 
abstract lacked sufficient information to determine its inclusion or exclusion, the full text was 
retrieved.  Both reviewers assessed relevance of studies as per the inclusion criteria stated 
above, and any discrepancies were resolved by discussion. Studies that did not meet criteria 
were excluded. Full-text screening for eligibility was completed for 64 articles. Inter-rater 
reliability was calculated at both stages of screening. The level of agreement as indicated by 
Cohen’s Kappa was 0.88 at the title and abstract screening stage, and 0.94 at full-text stage 
indicating almost perfect agreement between reviewers. Where there were any differences, 
these were discussed between reviewers and an agreement reached.  
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Data extraction  
Following de-duplication of studies, study selection was completed by initially 
screening titles and abstracts for inclusion, followed by screening of all remaining relevant full-
text articles. The lead reviewer screened first, followed by the third author. Disagreements were 
resolved through discussion in order to reach a consensus. 
 
Following quality assessment of included studies, data extraction was completed 
systematically by the lead author. The primary reviewer independently extracted the data from 
included articles, and for accuracy, the second reviewer checked table entries.  
 
The following data was extracted, where available: first author, title, year of 
publication, journal, study design, aims, population characteristics (women and/or newborn 
infants), country/location of recruitment, study setting, the year(s) in which data collection took 
place, prevalence/incidence of PAE (n, %) via self-reported data (n, % & 95% confidence 
intervals), assessment tool used to obtain self-report PAU, level of agreement, maternal sample 
characteristics (age, sample size, socio-economic status, ethnicity, level of education), 
trimester of PAE, infant sample characteristics (sex, sample size, ethnicity, gestational age at 
delivery [in weeks], head circumference, length in cm at birth), biomarker utilised, estimates 
of prevalence/incidence of PAE via meconium testing (n, % & 95% confidence interval), 
cumulative FAEE cut-off concentration used, EtG & EtS cut-off, details of collection, analysis 
used, testing and storage of meconium, inclusion and exclusion criteria, primary outcome and 
secondary outcomes.   
 
Evaluation of methodological quality  
Methodological quality and risk of bias was assessed with a tool specifically employed 
for systematic reviews addressing questions of prevalence; the “Joanna Briggs Institute Critical 
Appraisal Checklist for Studies Reporting Prevalence Data” (Joanna Briggs Institute [JBI], 
2017). Developed by Munn et al. (2015), this checklist comprises nine items, each with four 
standard answer options, and a further item for the overall appraisal of the study based on the 
rater’s judgement. A systematic review comparing all available instruments designed to 
appraise risk of bias for prevalence studies concluded that the JBI tool was the most appropriate 
with higher methodological rigour than its counterparts (Migliavacha et al., 2020).  
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The tool was used to guide evaluation of included studies across the following criteria: 
representative sample frame, appropriate recruitment, adequate sample size, detailed 
description of study subjects and setting, data analysis, methodology used, validity of 
methodology, reliability of measurement of the condition of interest, appropriate statistical 
analysis and adequate response rate. Study quality was independently assessed by both 
reviewers to ensure consistent application of the tool and to improve validity and accuracy. 
Discrepancies were resolved by clarifying details of the items and a consensus reached via 
discussion. No studies were excluded based on the quality assessment. 
 
Statistical analysis  
The review aimed to establish a pooled estimate of the prevalence of PAU as indicated 
via meconium biomarkers. Data on prevalence was gathered from all included studies and 





Search results  
Electronic searches and additional sources yielded a total of 505 citations. Following 
removal of duplicates (n = 58), 445 citations were screened using title and abstracts. A further 
382 records were excluded at this stage as they did not meet inclusion criteria. Subsequently, 
63 full-text articles were assessed for inclusion, 49 of which were excluded. A total of 12 
studies fulfilled the inclusion criteria and were retained for data extraction. A schematic 
diagram is illustrated below in Figure 2.  
 
Importation of citations and screening and exclusion of records were managed using 
the Covidence Systematic Review Management Software ( https://www.covidence.org/ ). Two 
of the included studies at the data extraction stage were found to be duplicated data: Nightingale 
(2016) was a doctoral dissertation of a published study (English et al., 2016) published in 
iteration, and therefore studies were merged and reported as a single study. Similarly, Derauf 
et al. (2003) and Moore et al. (2003) were merged as following data extraction and contact 





























Systematic Literature Search and Study Selection Process Illustrated using PRISMA Flow 












Characteristics of included studies 
 
Key characteristics  
Study characteristics and demographic information are summarised in Tables 1 and 2. 
All studies were published in peer review journals. One study was published in 2003 (Derauf 
et al., 2003) and the remaining between 2010 and 2019. Studies included data on prevalence 
across four continents including Europe, North America, South America and Africa. Study 
designs were cross-sectional population-based studies or cohort studies, with one being 
voluntary in nature (Delano et al., 2019).  
 
Maternal characteristics  
Samples were recruited from maternity settings such as general hospitals, prenatal 
clinics, birthing hospitals, neonatology wards or obstetrics units. In terms of characteristics of 
maternal samples, nine studies reported age ranges of the mothers in the studies. Ages ranged 
from 24.9 years (English et al., 2016) to 32.3 years (Bana et al., 2014). Sociodemographic 
factors were reported inconsistently as only half of the studies reported either socioeconomic 
status (SES), income or employment status. The samples of two studies had low SES 
(Abernethy et al., 2018; Hutson et al., 2010), the majority of one sample earned less than 
$19,999 per annum (Bakhireva et al., 2019), whilst the majority of another study (Delano et 
al., 2019; 57.8%) had an income of >$80,000. Employment rates were 72% in Bana et al. 
(2014) and 75.4% in Lamy et al. (2017).  
 
Five studies reported information on the level of education obtained and marital status. 
The majority of the women recruited in three of these studies had completed secondary/high 
school and/or college/university degree: 73.7% in Bakhireva et al. (2019); 72% in Bana et al. 
(2014); and 54.5% in Lamy et al. (2017). In comparison, 55% of women in English et al. (2016) 
were categorised as having primary/no education, and 95% of Hutson et al. (2010) had 
completed less than secondary level education. Regarding marital status, the vast majority of 
women in three studies were married or cohabiting: 83.5% in Bakhireva et al. (2019), 95.3% 
in Delano et al. (2019), and 94% in English et al. (2016). Whereas in Hutson et al. (2010) only 
18% of the sample were married.  
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The use of tobacco varied greatly amongst the studies, as well as the manner in which 
this was reported. Some studies specified prevalence rates of tobacco use during pregnancy: 
13.3% (Derauf et al., 2003), 5.9% (Delano et al., 2019), 0.2% (English et al., 2016) and 17.1% 
during the 3rd trimester (Lamy et al., 2017). Others reported tobacco use but did not specify 
whether this was during pregnancy or prior to (Abernethy et al., 2018; Hutson et al., 2010; 
Sanvisens et al., 2016).  
 
Information on whether the mother had had previous pregnancies or births prior to the 
one reported on in the study was also collected by half of the studies. The rate of women who 
had never given birth ranged from 29.7% (Bakhireva et al., 2019) to 44% (Delano et al., 2019), 
and those who were pregnant for the first time (primigravida) ranged from 9.9% (Pichini et al., 
2012) to 40.4% (Delano et al., 2019).  
 
Infant characteristics 
All samples were neonates born in maternity settings. Infants born in high-risk settings 
were excluded. Mean gestational age of delivery was similar across studies that detailed this (n 
= 5) and ranged from 38.7 weeks (Bakhireva et al., 2019) to 39.7 (Abernethy et al., 2018). 
Average birth weights were also similar and ranged from 3.25kg (Pichini et al., 2012) to 3.46kg 


















Participant Characteristic Table   
Maternal characteristics Infant characteristics 
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Methodological quality review 
The agreed ratings for each item on the quality assessment tool are displayed in Table 
3. The number of criteria met ranged from three (Sanvisens et al., 2016) to eight and the average 
criterion fulfilled was six out of nine. Two studies fulfilled eight out of nine criteria (Hutson et 















































































































































































Bakhireva (2019) ✓ ✓ ✓ ✓ NA ✓ ✓ ✓ ✕ 
Bana (2014) ✓ ✓ ✕ ✓ NA ✓ UN UN ✓ 
Bryanton (2014) UN ✓ ✓ ✕ NA ✓ ✓ ✓ ✓ 
Delano (2019) ✓ ✓ ✓ ✕ NA ✓ ✓ ✓ ✓ 
Derauf (2003) UN ✓ ✓ ✕ NA ✕ ✓ UN ✓ 
English (2016) ✓ ✓ ✓ ✓ NA ✓ UN UN ✓ 
Gareri (2008) UN ✓ ✓ ✕ NA ✓ ✓ ✓ ✓ 
Hutson (2010) ✓ ✓ ✓ ✓ NA ✓ ✓ ✓ ✓ 
Lamy (2017) ✓ ✓ ✓ ✓ NA ✓ ✓ ✓ ✓ 
Pichini (2012) ✓ ✓ ✓ ✓ NA ✓ ✓ ✕ UN 
Sanvisens (2016) ✓ UN ✕ ✕ NA ✓ ✓ UN ✕ 
Note. ✓ Yes (item adequately addressed); ✕ no (item not adequately addressed); UN unclear 
(item not stated); NA not applicable
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In terms of methodological strengths within included studies, three out of four studies 
were deemed to have a representative sample. Although the majority of studies did not report 
sample size calculations, the reviewer conducted these as per the quality assessment tools 
guidance on epidemiological studies using Naing et al.’s (2006) statistical formula. Using the 
prevalence of PAU rate of 18.9%, as obtained via meconium measures in a systematic review 
and meta-analysis conducted by Popova et al. (2017), a minimum sample size of 236 was 
required. All studies with a sample of 236 or above therefore met this criterion, which equated 
to 80% of studies in this review.  
 
A major strength noted during the quality appraisal process was the clear description 
for the rationale of each study and its main objectives. Furthermore, all studies, with the 
exception of Sanvisens et al. (2016), demonstrated appropriate recruitment of the sample and 
described this in a comprehensive manner. Random sampling methods were employed by two 
studies (Abernethy et al., 2018 & Bana et al., 2014), whilst nine others utilised consecutive 
sampling over a designated time period. Appropriate description of response rates was 
provided for all studies with the exception of Bakhireva et al. (2019), Pichini et al. (2012) and 
Sanvisens et al. (2016). Additionally, inter-rate reliability of the quality appraisal indicated 
almost perfect agreement between reviewers, as demonstrated by a Cohen’s Kappa value of 
0.87. Discrepancies were resolved via discussion.  
 
Methodological weaknesses were also observed; five of the studies failed to describe 
the sample or setting in sufficient detail (Bryanton et al., 2014; Derauf et al., 2003; Delano et 
al., 2019; Gareri et al., 2008; Sanvisens et al., 2016). One quarter of studies did not specify 
exclusion criteria (Bakhireva et al., 2019; Bryanton et al., 2014; Derauf et al., 2003; Sanvisens 
et al., 2016). A major concern noted was the inconsistency in the reporting of prevalence data, 
and how rates and proportions were calculated. Different units of measurement of PAE and 
cut-off points, as well as different expressions of prevalence data were complicating factors in 
the included studies and limited the ability to draw comparisons across studies.  50% of the 
studies either did not conduct appropriate statistical analysis as they did not utilise 
recommended cut-off points for analysis or were unclear in their reporting of methodology and 
analytical strategies utilised (Abernethy et al., 2018; Bana et al., 2014; Derauf et al., 2003; 
English et al., 2016; Pichini et al., 2012; Sanvisens et al., 2016). Only three of the quality 
criteria were met in Sanvisens et al. (2016); this study did not demonstrate adequate sample 
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size or management of response rate and failed to provide adequate description of the study 
subjects and setting. 
 
 Even within studies analysing FAEE’s alone, there was no consensus on the number 
of FAEE’s summed to calculate prevalence, and some studies did not specify this in their 
methodology. Furthermore, the ‘limit of detection’ (LOD), i.e., the lowest quantity of a 
concentration that can be measured was inconsistent with the laboratories conducting these 
analyses using different reference points (as illustrated in table 4). For example, Gareri et al. 
(2008) utilised an LOD of 50ng/g, which could have resulted in different prevalence rates if 
the typical LOD of 100ng/g was used. 
 
The appraisal process highlighted further methodological concerns. Not all studies 
clearly specified inclusion and exclusion criteria or provided an adequate description of study 
characteristics and sociodemographic information, thus limiting potential for replicability and 
transferability of results across cohorts and countries. Additionally, some studies did not 
specify detailed procedures of meconium collection and storage, thus prohibiting the evaluation 
of the validity and methodological rigour of the findings of those studies. Meconium samples 
require careful collection and preservation in order to avoid the possibility of contamination, 
and improper storage can increase the possibility of false-negative results (Gray & Huestis, 
2007). More specifically, FAEEs are sensitive to light and temperature, and samples degrade 
by approximately 86% within a 24-hour period when stored at room temperature. As such, 
samples require storage almost immediately following collection, in a -20 ℃ freezer (Moore et 
al., 2003). The procedures around collection of meconium of studies in this review varied in 
the detail with which they were reported and conducted, however (as illustrated below in Table 
4). In this review, eleven of the studies described storage procedures and only seven of these 
adhered to this protocol.  
 
The timing of collection is also paramount as one study conducted by Zelner et al. 
(2012) found that false positive FAEE results can occur as a result of delayed sample collection. 
The authors proposed that results of meconium analysis should be interpreted with caution for 
samples passed after the first 24 hours following birth, or samples collected after the first 
meconium sample was passed, due to the possibility of contamination and elevated FAEE’s. 
Not all samples in this review were collected within the recommended 24-hour period, nor 
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were they first samples. Only one study specified collection of samples within 24 hours 
following the birth (Bryanton et al., 2014), although authors noted that not all samples of 
meconium were the first ones excreted. Lack of information on timing of collection was 
observed across half of the studies thus highlighting a concern around methodological rigour.  
 
Lastly, the majority of studies (n = 9) required informed consent from the mother for 
meconium samples to be collected and/or analysed. Exceptions were Bryanton et al. (2014) 
and Gareri et al. (2008) whereby collection of samples was anonymous and so did not require 
consent, however once informed of the study post-birth mothers retained the right to withdraw 
consent. For example, meconium analysis was conducted on 52% of one cohort (Bakhireva et 
al., 2019). Therefore, it was possible that women who did drink during pregnancy chose not to 










Meconium analysis and prevalence of PAE 
Due to the heterogeneity of the studies, a meta-analysis was deemed inappropriate. 
Differences across biomarkers utilised and their respective cut-off points, inconsistencies in 
reporting outcomes, and diversity of protocols surrounding meconium collection and storage 
procedures precluded a statistical synthesis of the included studies. A narrative synthesis of the 
data is therefore presented. 
 
Data on the prevalence of prenatal alcohol exposure as obtained using meconium 
biomarkers are illustrated in Table 5 below. With respect to biomarkers utilised, FAEE’s were 
used to assess prevalence in all but two studies; Lamy et al. (2017) used EtG, and Sanvisens et 
al. (2016) used EtG and EtS. However, the manner in which prevalence rates were calculated 
differed between studies. Only five studies employed the internationally accepted cumulative 
cut-off point for FAEE analysis of 2nmol/g (Bryanton et al., 2014; Delano et al., 2019; English 
et al., 2016; Gareri et al., 2008; Hutson et al., 2010). Other studies used different measurement 
units of FAEE, for example Abernethy et al. (2018) used a cut-off point of >600ng/g. 
Conversion of units demonstrated that based on a molecular weight of 280g/mol, 2nmol/g 
equates to approximately 560ng/g. Therefore, results of this study were found to be comparable 
with the previous 5 studies reporting rates in terms of nmolg/g. However, the cut-off used by 
Bana et al. (2014) at 1000ng/g was much higher than recommended, reflecting the possibility 
of underestimation of prevalence.  
 
Four studies reported prevalence based on EtG and/or EtS analysis, although these also 
differed in the cut-off points used. Only one study (Abernethy et al., 2018) used the 
recommended cut-off of 30ng/g, whilst the other three used more conservative cut-offs of >40 
ng/g (Lamy et al., 2017), >50 ng/g (Bana et al., 2014) and >274 ng/g (Sanvisens et al., 2016). 
Additionally, while the majority of studies reported prevalence as per individual biomarker and 
cut-off point, three studies did not and reported prevalence as indicated by either a positive 
result of ≥ 2 biomarkers (Bakhireva et al., 2019), or a summation of biomarkers (Bana et al., 
2014; Sanvisens et al., 2016).  
 
Overall, the prevalence of PAE as indicated by FAEE biomarkers in meconium ranged 
from 2.4% (Delano et al., 2019) to 44% (Hutson et al., 2010). Rates based on EtG results ranged 
from 2.9% (Lamy et al., 2017) to 15% (Abernethy et al., 2018), and EtS prevalence rates were 
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between 7.8% (Bakhireva et al., 2019) and 16.7% (Sanvisens et al., 2016). When investigated 
by geographical region, the highest rate was observed in Uruguay at 44% (Hutson et al., 2010), 
followed by Scotland at 42% (Abernethy et al., 2018). Rates in Spain were as low as 4.2% in 
one study (Sanvisens et al., 2016) and as high as 34.6% in another (Bana et al., 2014), despite 
cut-off points being much higher in the latter study (FAEE >1000ng/g/ and EtG >50 ng/g vs 




Bar Chart Depicting the Prevalence of PAE Based on Author, Year and Country as Determined 




Self-report prenatal alcohol use  
All studies with the exception of Bryanton et al. (2014) collected information on self-
reported PAU (illustrated in Table 5). Descriptive analysis of these results was explored, as 
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analysis in the studies which assessed this. However, results should be interpreted with caution 
as included studies are not representative of all studies utilising self-report methodology.  
 
Prevalence rates based on self-report data ranged from 0.5% in Ontario, Canada (Gareri 
et al., 2008) to 37% in Uruguay (Hutson et al., 2010). Timing of reported alcohol consumption 
differed from “risky’ alcohol consumption 12 months prior to pregnancy (Bakhireva et al., 
2019) to 3rd trimester drinking (Lamy et al., 2017), and ‘any’ use throughout pregnancy 
duration (English et al., 2016). Collection and analysis of this data also varied greatly, as studies 
used different methods including questionnaires (Abernethy et al., 2018; Bana et al., 2014; 
Bryanton et al., 2014; Gareri et al., 2008; Hutson et al., 2010; Sanvisens et al., 2016), semi-
structured interviews (Lamy et al., 2017), and validated alcohol screening measures including 
the AUDIT (Pichini et al., 2012), AUDIT-C (Bakhireva et al., 2019), TWEAK (English et al., 
2016) and CAGE (Hutson et al., 2010). Half of the studies conducted analysis on 
comparability/level of agreement between self-reported PAU and PAE as obtained via 
meconium biomarkers. Four of these found that there was no agreement between self-reported 
PAU and detection of positive biomarkers in meconium (Derauf et al., 2003; Delano et al., 
2019; English et al., 2016; Pichini et al., 2012), whilst two found poor levels of agreement as 
demonstrated by Kappa values of 0.06 (Hutson et al., 2010) and 0.13 (Lamy et al., 2017).  
 
Overall, prevalence rates obtained via meconium testing were higher than self-reported 
PAU amongst the same sample in six of the eleven studies (Abernethy et al., 2018; Bana et al., 
2014; Derauf et al., 2003; Gareri et al., 2008; Hutson et al., 2010; Sanvisens et al., 2016). 
Biomarker determined rates ranged from 1.2 times higher (in Uruguay; Hutson et al., 2010) to 
14 times higher (in Scotland; Abernethy et al., 2018) than those obtained by maternal self-








Study Results Table Reporting Prevalence of PAU using Meconium Testing & Maternal Self-reports 
 



















235 42% (FAEEs), 
15% (EtG) 
325 3% Informal 
questionnaire 
- 
Bakhireva FAEEs, EtG, 
EtS 
Ethyl laurate (>LOQ: 50 
ng/g), ethyl myristate (> 
LOQ: 250 ng/g), ethyl 
palmitate (> LOQ: 50 
ng/g), ethyl palmitoleate 
(> LOQ: 15 ng/g), ethyl 
stearate (> LOQ: 50 
ng/g), ethyl oleate (> 
LOQ: 15 ng/g), ethyl 
linoleate (> LOQ: 15 
ng/g), ethyl linolenate (> 
LOQ: 25 ng/g), and ethyl 
arachidonate (> LOQ: 15 
ng/g). EtG >LOQ: 3.ng/g, 
EtS > LOQ: 5.0ng/g. * 
LC-
MS/MS 
333 7.8% (EtS), 5.1% 
(EtG); 5.4% 
positive for ≥2 
biomarkers 
289 12.5% for “risky” 






Bana FAEEs, EtG FAEE >1000 ng/g, EtG > 




101 34.65%; 17% 
positive for both 
110 4.50% Questionnaire  - 




- - - - 
Delano FAEEs FAEE ≥ 2 nmol/g SPME 
GC-MS 
1315 2.4% 1315 32% “social level” 
drinking during 
pregnancy 
- No agreement  
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Derauf FAEEs FAEE ≥ 50 ng/g GC/MS  422 17.10% 436 5.30% Questionnaire No agreement 
(k = –0.02, 
95%CI: –0.04, 
0.00) 
English FAEEs  FAEE > 2 nmol/g GC/MS  503 11.2 % 505 16% “any” use during 
pregnancy, 3.2% 
“consistent use”, 6.3% 
‘‘heavy consumption’’ 
during any trimester. 
TWEAK results: Of 
n= 81 who reported 







(p =  0.118) 
Gareri FAEEs  FAEE ≥ 2.00 nmol/g. GC/MS  682 2.50% 1019 0.50% Questionnaire - 







(k = 0.06; 95% 
CI: –0.02 to 
0.14) 





(k = 0.13; 
95%CI: 0.04-
0.22) 
Pichini FAEEs, EtG, 
EtS 
FAEE & EtG ≥ 2 nmol ⁄g LC/MS/M
S 
607 7.9%  (0% in 
Verona, 4.0% in 
San Daniele del 
Friuli, 4.9% in 
Naples, 5.0% in 
Florence, 6.2% in 
Crotone, up to 
10.6% in Reggio 
Emilia, and 29.4% 
in Rome) 
607 28.9%  AUDIT 
questionnaire 
No agreement  




48 4.2% (EtG), 16.7% 
(EtS) 
51 6% Structured 
questionnaire 
- 





This review investigated the prevalence of PAE as obtained using meconium 
biomarkers of alcohol. Following a comprehensive systematic search of the literature, twelve 
studies reporting the prevalence of PAE using meconium biomarkers were identified and their 
methodological quality assessed. The review initially proposed to estimate a global pooled 
prevalence of PAE and identify prevalence rates by geographical location of the studies. This 
was not viable however due to the heterogeneity observed across studies with regards to large 
variation across methodology and analysis.  
 
Interestingly, prevalence rates varied widely across the twelve studies.  The lowest 
prevalence rate of PAE from meconium testing reported was 2.4% (Delano et al., 2019) and 
the highest rate 44% (Hutson et al., 2010). The former, a Canadian birth cohort study, recruited 
2,000 volunteering women, the majority of whom were married (95%) and earning a gross 
annual income of over $80,000. The latter was a cross-sectional study conducted in Uruguay 
in a low socioeconomic sample of women; 18% of whom were married and 95% of whom had 
completed less than secondary level education. Similarly, a high prevalence rate of 42% was 
observed in a study recruiting from an inner-city maternity unit in Glasgow, Scotland 
(Abernethy et al., 2018). These results taken as a whole reflect findings from US literature, as 
higher risks of drinking have been observed amongst unmarried women, and more specifically, 
higher risk of 3rd trimester drinking amongst lower income groups (Shmulewitz & Hasin, 
2019).  
 
These studies are from different continents however, and this must be acknowledged in 
addition to the many other sociodemographic factors at play. A common misconception is that 
PAU is associated with poverty, and although Abernethy et al. (2018) demonstrated a high 
prevalence of PAU in their sample, which was predominantly of lower SES, they also found 
with subgroup analysis that positive meconium results were more common in women living in 
more affluent areas. Studies have demonstrated that women of higher SES report more frequent 
PAU than those of lower SES, while rates of FASD are higher in lower SES cohorts, possibly 
due to heavier consumption or binge drinking (May & Gossage, 2011; Shmulewitz & Hasin, 
2019). Increased rates of inadequate prenatal care and social complexities are also factors 
related to higher rates of FASD (Singal et al., 2019), which are more prevalent in lower SES 
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groups. Regarding marital status, one possible explanation for higher rates of PAU in 
unmarried women may be lack of social support, which has been found to be a protective factor 
for reducing alcohol use in women (Leonardson & Loudenburg, 2007). Nonetheless, this 
highlights some of the many factors associated with PAU, which must be considered when 
interpreting prevalence rates.  
 
Measurement of PAU also plays a role. A previous systematic review found that 
prevalence estimates based on meconium biomarkers were on average four times higher than 
those obtained using self-reports (Lange et al., 2014). In this review, 11 studies provided 
information on self-reported PAU, however only six of these indicated higher prevalence rates 
from meconium testing. Within these six studies, positive meconium results ranged from 1.2 
to 14 times higher than self-reported rates of PAU. With regards to the other five studies, self-
reported rates were higher than positive meconium biomarker rates, however this might be 
explained by the manner in which self-report data was collected. For example, Bakhireva et al. 
(2019) reported alcohol consumption in the 12 months prior to enrolment to the study, thus 
capturing consumption during pre-pregnancy and pregnancy stages. Additionally, Delano et 
al., 2019 found self-reported prevalence to be 13 times higher than the rate of positive 
meconium biomarkers (32% of social level drinking versus 2.4%). This ‘social drinking level’ 
equated to less that 2 standard drinks per week however, and only 0.2% of women reported 
drinking above this level, a rate tenfold lower than that found by meconium FAEE analysis. 
These highlight the limitations of self-report, particularly in detecting heavier alcohol 
consumption which objective measures appear to be more sensitive to.  
 
Irrespective of the means of measurement, the global prevalence of PAU has been 
estimated at 10% (Popova et al., 2017), however half of the studies in this review had rates 
below this. Comparison of prevalence rates of alcohol use and alcohol exposure is complicated 
by a multitude of factors however, one being the methodology utilised to ascertain the data. As 
meconium testing typically reflects moderate to heavy exposure to alcohol during the later 
stages of pregnancy, women who drink modest amounts earlier on might not be detected. 
Conversely, this increases the possibility of false negative errors, represents missed 
opportunities to adequately support individuals with PAE and their families (Gifford & Bearer, 
2015) and to possibly ameliorate effects of PAE by implementing neurodevelopmental 
interventions (Wozniak et al., 2020). Some authors have therefore suggested that self-report 
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measures are more effective at detecting lower PAE than objective measures despite likely 
underreporting (McQuire et al., 2016).  
 
Strengths & limitations  
The current review is the first of its kind and has several notable strengths, including 
the extensive search strategy, rigorous critical appraisal and application of stringent inclusion 
and exclusion criteria. Overall, the methodological quality of included studies was satisfactory. 
All studies were recruited from general maternity or antenatal settings, thus increasing the 
applicability of findings to general population samples in each respective geographical 
location. The majority of studies had adequate sample sizes for assessing prevalence rates 
(80%). Furthermore, 11 studies had recruited appropriately through either random or 
consecutive sampling, thereby increasing generalisability of results.  
 
This review is not without its limitations, however. One significant shortcoming 
observed across the studies was the heterogeneity of analysis and methods employed. Only six 
studies used internationally accepted cumulative cut-off points for FAEE analysis and one for 
EtG analysis. Additionally, Lamy et al. (2017) found a high rate of false negative results from 
EtG biomarker analyses, further demonstrating the need to approach results of such tests with 
caution. In support of these findings were conclusions drawn from a meta-analysis conducted 
by McQuire et al. (2016). Authors found a lack of consensus across the levels of acceptability 
for diagnostic accuracy of biomarkers and high rates of false positive and false negative tests.  
 
Although FAEE, EtG & EtS are validated biomarkers of PAE, there is no standardised 
quantification criteria for their analysis. In this review, some authors specified the FAEE’s 
cumulated for analysis of prevalence rates, whilst others did not provide this information. Other 
studies reported prevalence based on the analysis of two positive biomarkers instead of one. 
Cut-off points for each biomarker also differed, with FAEE cut-off points ranging from 600 
ng/g to 1000 ng/g, and EtG from 30 ng/g to 50 ng/g. There is lack of consensus regarding cut-
off points for biomarkers, with some studies proposing that cut-off concentrations for FAEE’s 
should be 10,000 ng/g (approx. 33 nmol/g) and others ranging from 200 ng/g to 600 ng/g 
(Delano et al., 2019). Consequently, sensitivity and specificity rates of these cut-offs vary 
considerably between 52%-100% and 43.1% to 98.4% respectively (Chan et al., 2004; Himes 
et al., 2015), although are highest with a cumulative cut-off of 2.0 nmol/g (Chan et al., 2003). 
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As a result, pooling estimates of prevalence rates is difficult across studies that appear 
homogenous in terms of recruitment and design but differ in their procedures and statistical 
analysis.  
 
Limitations of review 
Application of the eligibility criteria identified 12 studies for inclusion in this review, a 
reasonably small number given that research investigating the prevalence of PAE via 
meconium biomarkers began in the 1990’s (Bearer et al., 1996; Mac et al., 1994; Niemelä et 
al., 1991). Furthermore, this review only included studies conducted in general maternity 
populations. In choosing to review the prevalence of PAU in general populations, the relevance 
of these findings to high-risk neonatal populations such as in Chan et al. (2004) is limited. 
Nonetheless, piloting of the search strategy and independent screening and assessment of 
quality by two reviewers permits confidence that the conclusions drawn from this systematic 
review are based on the synthesis of all available evidence in the area. 
 
Generalisability 
The heterogeneity of studies limits the ability to determine overall prevalence and to 
draw comparisons between countries. Recruitment methods varied, as well as procedures 
around the collection, storage and analysis of samples. Given the requirement for consent or 
voluntary nature of most studies, it is possible that some women who had consumed alcohol 
during pregnancy choose not to consent to the study or to provide meconium sample for 
analysis. These may have led to conservative prevalence rates and jeopardised the 
generalisability of findings.  
 
Despite the above, findings reflect the diversity of the literature with respect to the 
varying levels of PAU observed across populations and geographical locations. It highlights 
the importance of collecting detailed maternal information in order to determine differences in 
prevalence between subgroups and explore the impact of sociodemographic factors on 
prevalence of PAU. Findings of each study in isolation can be utilised as per country and may 
be helpful in determining the risks of PAE within certain populations and regions so that 
universal screening strategies can be implemented. The discordance between rates of self-
reported PAU and PAE as determined by meconium biomarkers further emphasizes the need 
for caution when interpreting results, but also raises the question as to whether objective 
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measures should be utilised in conjunction with subjective measures in order to better detect 
PAE at various stages throughout pregnancy. Objective measures may increase the accuracy 
of figures derived from self-report.  
 
Implications 
The current review demonstrates the sparsity of methodologically robust prevalence 
studies using meconium biomarkers and highlights an ongoing need for further research and 
clinical recommendations in antenatal care settings regarding the utility of meconium 
biomarkers. Alcohol consumption in pregnancy is a highly emotive topic and screening 
programmes need to be accurate and acceptable to the population. The WHO proposes that 
parameters for screening programmes must be set based on best evidence, cost-efficacy and 
feasibility (WHO, 2020). Evidently, more research is required to establish reliable and concrete 
evidence for objective measures, and to assess the most feasible methods for individuals, 
clinicians and stakeholders (McQuire et al., 2016). Further studies should explore the 
correlation of self-report measures with FAEE and EtG concentrations and should ensure they 
are utilising internationally recommended cut-off points. Methodological rigour is crucial in 
order to provide more reliable evidence regarding the clinical and scientific use of biomarkers 
and to allow for comparison across studies. Enhancing the accuracy of prevalence data on PAE 
would have far-reaching effects on the assessment and diagnoses of FASD, as it would help to 
facilitate assessment of risk and implementation of timely interventions.  
 
This review included studies examining FAEE, EtG and EtS in meconium. There is a 
paucity of research on EtS, and only three of the studies in this review utilised this measure. 
Thus, conclusions drawn on the basis of EtS analysis are limited, and the evidence for its value 
in detection of PAU requires further research. Thresholds also need further consideration and 
more testing in general antenatal settings is required. The 2nmol/g cut-off for FAEEs is based 
on a study comparing women with alcohol problems to abstainers (Chan et al., 2003), and this 
raises a query as to whether it is appropriate for use in general populations. Recommendations 
for consistent and specific guidelines on the analysis of meconium biomarkers should be a 
focus of future research and policy makers.  
 
As mentioned, meconium is produced in second and third trimesters and therefore 
positive biomarkers indicate PAU during these later stages of pregnancy. Meconium FAEE’s 
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are limited in their ability to detect infrequent, but potentially harmful consumption during 
earlier stages (Bryanton et al., 2014). Thus, utilising such measures is likely to miss a 
proportion of women who have consumed alcohol in earlier stages but ceased during the course 
of the pregnancy or following recognition. Self-report methods may be more effective to 
capture this pattern of consumption, however, are vulnerable to recall and reporting bias and 
this may lead to underestimation of prevalence rates of PAU. Future research should ensure 
standardised self-report measures are employed which are appropriate for assessing PAU in 
general and non-high-risk pregnant populations. The AUDIT-C (Bush et al., 1998) has been 
validated in antenatal settings (Scottish Intercollegiate Guidelines Network [SIGN], 2019).  
 
Currently diagnoses of FASD remains a challenge as the most common method 
employed to obtain information regarding PAU is self-report. Due to factors such as stigma 
and shame, it is unlikely that studies relying on maternal self-report alone can accurately 
estimate the prevalence of either PAE or FASD. If infants are not identified as at risk of FASD, 
appropriate screening and interventions cannot be implemented. This creates a perpetuating 
problem across the globe as individuals likely to be affected lack access to necessary 
provisions, which in turn result in more adverse outcomes. Improving methods used to obtain 
data on PAU would have far-reaching effects on diagnostic services, implementations for 
public health policies and recommendations for public health. Prevalence rates based on 
objective measures within general population samples are likely to be a closer true estimate of 
PAE.   
 
Lastly, results of this review highlight the need to consider the links between social 
determinants of health and FASD. The evidence is clear that the direct cause of FASD is PAE, 
however drinking behaviour is affected by a multitude of social, economic and cultural factors 
such as poverty, genetics, adverse life events and poor social support systems around the 
individual (Jonsson et al., 2014). These need to be considered in the context of FASD, and in 
this review, higher rates of PAE as indicated by meconium were observed in lower 
socioeconomic status groups. Differentiating between higher-risk and lower-risk community 
samples is important both in the research conducted in this area and in the implementation of 
prevention strategies in order to improve efficacy and ensure acceptability of such interventions 
amongst different cohorts. These factors, as well as the inconsistent methodologies employed 
within research to assess prevalence of FASD suggest that a high degree of caution is required 
when interpreting results of prevalence studies as these can have significant impacts on the 
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public health advice given to women. The literature on the best practices for screening of PAE 
is limited, as also observed in this review, and these further highlight some of the ethical 
challenges associated with use of meconium biomarkers for screening PAE. Results indicate 
the need to consider these ethical implications, and more broadly, the need to approach the 
research with sensitivity and caution.  
 
Conclusion 
This review found that the prevalence of PAE as detected using meconium biomarkers 
varied widely across the literature, ranging from 2.4% to 44%. Significant variation amongst 
study methodologies precluded the utility of establishing a pooled prevalence of PAU. 
Nonetheless, the review highlighted the diversity of prevalence rates across maternal 
populations in different countries and provides support for the need for public health initiatives 
to direct attention towards PAE.  Alcohol consumption during pregnancy is a growing public 
health issue, however capturing true prevalence rates remains a challenging feat. Gaining 
accurate estimates of the prevalence of PAU is vital for the assessment of potential risk, early 
diagnosis of FASD and access to adequate services. The implementation of appropriate 
screening programmes is a pivotal part of any primary prevention and early intervention 
approach for FASD. This review concludes that meconium biomarkers of PAE hold promise 
as an objective and valuable method, in comparison to self-report or questionnaires. However 
further research is required on its validity and acceptability to population-based samples in 
order to best inform screening strategies for use in routine clinical practice.  
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Appendix B Search Syntax  
 
 
Database Syntax  
Medline, Embase 
and PsycINFO 
(prevalen* or epidemiolog* or frequenc* or occur* or inciden* or probability 
or rate* or statistic) AND (pregnan* or prenatal or pre natal or antenat* or 
postnat* or primigravida or expect* mother* or expect* mum* or matern* 
or maternal-fetal exchange or newborn* or baby or Infant) AND (Alcohol* 
or binge drinking or ARBD or ARND or drunk* or ethanol or FAS or FASD 
or Intoxicat* or PAE or pFAS) AND (meconium or FAEE or "alcohol 
metabolite*" or "fatty acid* ethyl or ester*" or etg or "ethyl glucuronide*" 
or ets or "ethyl sulfate*") 
Proquest 
dissertations and 
Thesis Global  
Meconium OR prevalence OR prenatal OR alcohol OR pregnan* 
CINAHL Plus 
 
(prevalen* or epidemiolog* or frequenc* or occur* or inciden* or probability 
or rate* or statistic) AND (pregnan* or prenatal or pre natal or antenat* or 
postnat* or primigravida or expect* mother* or expect* mum* or matern* 
or maternal-fetal exchange or newborn* or baby or Infant) AND (Alcohol* 
or binge drinking or ARBD or ARND or drunk* or ethanol or FAS or FASD 
or Intoxicat* or PAE or pFAS) AND (meconium or FAEE or "alcohol 
metabolite*" or "fatty acid* ethyl or ester*" or etg or "ethyl glucuronide*" 
or ets or "ethyl sulfate*") 
SCOPUS (prevalen* or epidemiolog* or frequenc* or occur* or inciden* or probability 
or rate* or statistic) AND (pregnan* or prenatal or pre natal or antenat* or 
postnat* or primigravida or expect* mother* or expect* mum* or matern* 
or maternal-fetal exchange or newborn* or baby or Infant) AND (Alcohol* 
or binge drinking or ARBD or ARND or drunk* or ethanol or FAS or FASD 
or Intoxicat* or PAE or pFAS) AND (meconium or FAEE or "alcohol 
metabolite*" or "fatty acid* ethyl or ester*" or etg or "ethyl glucuronide*" 
or ets or "ethyl sulfate*") 
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Background: Prenatal alcohol consumption is a significant public health concern due to its 
teratogenic effects. Current WHO guidelines recommend that women should abstain from 
alcohol throughout their pregnancy, although prevalence rates remain high. This study explores 
the self-reported prevalence of prenatal alcohol use of pregnant, or recently pregnant, women 
in the UK and the impact of an educational intervention on attitudes and knowledge towards 
drinking during pregnancy.    
 
Methods: A national cross-sectional study recruited 1,536 women in the UK aged 19 to 50 
years (M = 33.3 years, SD = 4.89), from July 2020 to December 2020. An anonymous online 
questionnaire comprising an educational intervention and measures assessing prevalence, 
attitudes and knowledge was administered. 
 
Results: High rates of binge drinking were observed prior to pregnancy (82%), although 
decreased significantly following recognition of pregnancy (0.2%). One quarter of women 
reported drinking during pregnancy following recognition, and almost one in five women had 
not heard of the term FASD. The educational intervention had a significant impact (z = -9.67, 
p < .001 r = 0.29), and led to more negative attitudes towards prenatal alcohol use and improved 
knowledge of the associated risks.  Level of education and pre-existing attitudes were 
predictive of greater improvement [F (12, 1047) = 25.838, p < .001, adj. R2 = .22]. 
 
Conclusions: This study is the first of its kind to explore self-reported prevalence of prenatal 
alcohol use in the UK via an anonymous online survey, and the impact of an educational 
intervention on attitudes and knowledge. Findings support the utility of education interventions 
in improving knowledge of risks and increasing negative attitudes towards drinking during 
pregnancy. Implementation of such interventions at community and clinical levels is 
recommended to reduce prenatal alcohol consumption and subsequently, the prevalence of 
FASD.   
 
 






Women, alcohol, and pregnancy  
Alcohol consumption has increased globally, and the highest levels are observed in the 
WHO European Region (World Health Organisation, 2018). Women’s level of consumption 
in particular has risen steadily alongside cultural shifts in gender roles, increasing gender 
equality, and changes in attitudes towards drinking (Slade et al., 2016). Consumption during 
pregnancy, otherwise known as prenatal alcohol use (PAU), is a significant global health 
concern and the negative impacts of alcohol exposure in pregnancy are well established, 
including increased risks of miscarriage, preterm birth and foetal alcohol spectrum disorder 
(FASD). Global prevalence of PAU is estimated to be 9.8%, and the UK has the fourth highest 
estimated prevalence worldwide at 41.3% (Popova et al., 2017). 
 
International guidelines on PAU and what constitutes ‘safe’ levels of drinking during 
pregnancy have changed over time, leading to inconsistent messages from public health bodies. 
Until relatively recently, UK guidelines recommended that women should abstain from 
drinking during the pre-conception phase and first trimester, but if they choose to drink while 
pregnant, they should limit consumption to 1-2 units, once or twice a week (National Institute 
for Health and Clinical Excellence [NICE], 2008). However, in April 2016, the UK’s Chief 
Medical Officer’s (CMO) guidelines changed and advised that, given the absence of robust 
evidence, a ‘precautionary approach’ should be taken, and women should abstain from alcohol 
both during the pre-conception phase and throughout their pregnancy (Department of Health, 
2016). Current international guidelines echo this and recommend that pregnant women should 
abstain from alcohol consumption (Holland et al., 2016). This precautionary approach has 
sparked debate due to limited evidence surrounding the risks of low-level consumption.  
 
Ascertaining accurate estimates of the prevalence of PAU is challenging, and 
consumption during early stages prior to confirmation of the pregnancy is likely to be 
underreported or undetected. This is problematic as the foetus during the first trimester is 
particularly vulnerable to harm caused by alcohol (Schölin, 2016). In a multi-centre cohort 
study of 5,628 primigravida women across the UK, Ireland, New Zealand and Australia, one 
quarter reported low level PAU throughout (3-7 units per week) and a further 23% reported 
binge drinking (6 or more units in one session) during the first 15 weeks of pregnancy 
(McCarthy et al., 2013). The majority of women reduced their consumption or abstained 
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completely following recognition, a trend observed across research (Cameron et al., 2013; 
McCormack et al., 2017; Tough et al., 2006). However, unplanned pregnancies need to be 
considered as these can inevitably result in higher risks of inadvertent exposure of alcohol to 
the foetus (Schölin, 2016). In England, 45% of births are unplanned (Public Health England, 
2018).  
 
The heterogeneity of studies adds further complexity to the interpretation of prevalence 
rates as methodologies differ greatly. Self-report measures are likely to underestimate the level 
of PAU due to reporting and recall bias, and social stigma. Objective measures such as 
meconium biomarkers have been demonstrated to be more accurate, however cannot detect 
first trimester exposure (Lange et al., 2014). Definitions on what constitutes light, moderate 
and heavy consumption vary considerably across studies (Stade et al., 2009), and 
measurements of standard units of alcohol differ by country and type of alcoholic beverage, 
making it difficult to compare epidemiological studies (Clark et al., 1999). To improve 
collection of data on PAU several screening questionnaires have been developed and validated 
for use in antenatal settings. These are supported by clinical guidance and include the TWEAK, 
T-ACE, and AUDIT-C (Scottish Intercollegiate Guidelines Network [SIGN], 2019) 
 
Foetal alcohol spectrum disorder (FASD) 
FASD is an umbrella term used to describe a range of features that can occur as a result 
of PAU including structural or functional CNS abnormalities, cognitive and neurobehavioral 
impairments, and sentinel facial features (SIGN, 2019). Individuals with FASD often have 
difficulties with language, memory, learning and behaviour, as well as physical impairments. 
These can have lifelong implications, and place significant burden on the individual, their 
family and society. The economic burden is also high, with one study estimating the costs to 
be approximately 1.8 billion Canadian dollars per year (Popova et al., 2016), a population just 
over half of the UK’s. Due to the challenges associated with screening for PAU and subsequent 
diagnosis, the actual rate of FASD is unknown. A meta-analysis estimated FASD prevalence 
in the UK to be 32.4 per 1,000 population (Popova et al., 2017). Furthermore, a more recent 
population-based cohort study calculated a screening prevalence estimate of FASD in order to 
represent the proportion that would have retrospectively met criteria for FASD in the UK 
(McQuire et al., 2019). Authors evaluated data collected from 13,495 children born between 
1991 and 1992 and found a prevalence estimate of up to 17%.  
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Identification of babies exposed to alcohol is crucial for early diagnosis and 
intervention, and the absence of such can manifest in secondary adverse outcomes. A 
longitudinal study conducted by Streissguth et al. (1996) found that 94% of individuals with 
foetal alcohol effects experienced mental health problems, 60% of those aged 12 and over 
experienced trouble with the law, 79% had employment problems and a further 83% required 
dependent living situations. Diagnosis is challenging however and can be complicated by the 
overlapping features of genetic and malformation syndromes which share similar clinical 
characteristics to FASD, thus requiring careful differential diagnosis (British Medical 
Association, 2016). The continuing lack of consensus about what is considered ‘safe’ levels of 
consumption can impact on screening and diagnosis as women may or not meet certain criteria 
for exposure.  
 
Some studies have found evidence of harm with low level consumption and have 
demonstrated that PAU is associated with cognitive impairments in the areas of learning, 
attention, visuospatial memory, and cognitive flexibility (Burden et al., 2005; Jacobson & 
Jacobson, 2002; Streissguth, 2007). Others have argued that light to moderate drinking is not 
a risk factor for neurodevelopmental difficulties (Alati et al., 2008; Kelly et al., 2009; Kelly et 
al., 2013) or behavioural problems (Robinson et al., 2010). Nevertheless, a review of the 
literature concluded that that there is a narrow margin between levels of consumption before 
there is increased risk to the foetus and thereby supported guidelines advising abstinence 
(O’Leary & Bower, 2012).  
 
Interventions  
Numerous preventative approaches to reduce PAU and the incidence of FASD have 
been developed and implemented and can be classified into three categories. Universal 
prevention strategies aim to inform the general public of the risks associated with PAU and 
include public health interventions such as media campaigns and education interventions. 
Selective prevention strategies target women of reproductive age and populations at risk (e.g., 
women who drink during pregnancy) and include clinical interventions such as brief 
interventions (BI’s) and motivational interviewing. Indicated prevention strategies target 
women who are at high risk (e.g., require referral to specialist alcohol services) and incorporate 
pharmacological interventions (Clarren et al., 2011).  
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Regarding more targeted approaches for high-risk pregnant populations, the evidence 
for utility of pharmacological interventions is limited, as indicated by a systematic review 
conducted by Smith et al. (2009). Psychosocial interventions may show more promise, and 
motivation enhancement therapy has demonstrated efficacy in reducing alcohol and drug use 
in pregnant women receiving substance use treatment (Osterman et al., 2017). 
 
Selective and universal prevention strategies have received more attention in general 
pregnant populations, although the overall evidence for their use in antenatal settings is 
inconclusive. Reviews of randomised and non-randomised controlled trials have demonstrated 
support for their utility in improving knowledge and reducing PAU (Crawford-Williams et al., 
2015) as well as increasing abstinence rates (Stade et al., 2009; Gilinsky et al., 2011; Ujhelyi 
Gomez et al., 2020), however they also report significant heterogeneity and a paucity of 
methodologically robust studies. These authors concluded there was some evidence to suggest 
that BI’s are beneficial in supporting women to maintain abstinence during pregnancy. This 
was also demonstrated by O’Connor and Whaley (2007) who found that pregnant women that 
had undergone a BI were five times more likely to report abstinence, and their newborns more 
likely to have better outcomes when compared to a control group.  
 
BI’s have therefore been recommended as cost-effective preventative measures which 
can be practically delivered and have a robust evidence base, as demonstrated in an overview 
(O’Donnell et al., 2014). They involve an initial screening stage to identify hazardous drinking, 
and a time-limited structured conversation aimed to support the person to think about changing 
their drinking behaviours in order to reduce risk of harm (Scobie & Woodman 2017). Other 
techniques employed in brief educational and psychological interventions include motivational 
interviewing, education, goal setting, or assessment for alcohol dependency. Motivational 
interviewing interventions have also shown success in reducing the number of alcohol exposed 
pregnancies through lower PAU and more effective contraception use (Project CHOICES 
Intervention Research Group, 2003). BI and motivation interviewing based interventions are 
based on principles from social cognitive theory (Bandura, 1986), motivational enhancement 
(Miller & Rollnick, 2002), the transtheoretical model (Prochaska et al., 1993) and self-efficacy 
(Bandura, 1977).  
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Due to different techniques and theories underlying interventions, research has started 
to analyse interventions at a more fundamental level by investigating their ‘active ingredients’, 
known as behaviour change techniques (BCT’s). A meta-analysis conducted by Ujhelyi Gomez 
and colleagues (2020) found that the most commonly employed BCT’s in psychosocial 
interventions aimed at reducing PAU were information about health consequences, goal 
setting, social support, and action planning. These as well as behavioural contracts, problem 
solving, self-talk and assessing readiness to change have been found to be effective BCT’s for 
decreasing alcohol consumption (Fergie et al., 2019). 
 
Overall, the research illustrates large variability in the types of interventions delivered, 
making it difficult to determine those with the greatest efficacy. Brief educational and 
psychological interventions show most promise, and from an ethical perspective, are positive 
for the mother and the developing foetus. Furthermore, they are equitable, can be made easily 
accessible and delivered quickly, and generally have low implementation costs (Scobie & 
Woodman, 2017). Web-based interventions for individuals with alcohol use problems have 
also been on the rise over the past few years and offer a viable and cost-effective mode of 
delivery (Balhara & Verma, 2014). However, these have mainly been utilised in adolescent 
and student populations and have yet to be explored in pregnant populations. There is an 
apparent need for further research on interventions in antenatal settings in order to decrease 
PAU and incidence of FASD.  
 
Knowledge of risk and attitudes  
Provision of information on the risks associated with PAU and current guidelines may 
help to change attitudes and social norms around drinking (British Medical Association, 2016). 
This is supported by both general social marketing intervention research (Kubacki et al., 2015) 
and research demonstrating that universal interventions to raise awareness of PAU can impact 
on attitudes (Bazzo et al., 2015; Ihlen et al., 1993) and knowledge, thus having the potential to 
lower FASD prevalence (Chersich et al., 2012). Attitudes towards PAU and drinking 
behaviours during current and past pregnancies have been found to be the strongest predictors 
of PAU (Peadon et al., 2011; Peadon et al., 2010), however research is limited.  
 
International guidelines recommend that all pregnant women are screened for alcohol 
use by healthcare professionals (WHO, 2014), however, eliciting this information is 
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challenging due to potential stigmatisation, the negative attitudes of others, and concerns 
regarding child protection (Burns et al., 2010). Pregnant women who consume alcohol fear 
they will be perceived negatively by the public and healthcare professionals (Bell et al., 2016), 
may be concerned about the possible harm to their baby and, are therefore dissuaded from 
disclosing this information (Jones et al., 2011; Muggli et al., 2015).  
 
Knowledge also plays a role, and research has shown that many women do not 
understand risks of harm associated with PAU with 20% of women having a “tolerant” attitude 
towards it (Elliott, 2014). Qualitative research on women’s perceptions of the information and 
advice given around PAU reports ongoing confusion around safe levels of consumption and 
inconsistent messages (Anderson et al., 2014; Latuskie et al., 2019), and changes to guidance 
over time is likely to have exacerbated this. Women’s attitudes towards guidance can impact 
on their decision to consume alcohol. Holland et al. (2016) investigated women’s perception 
of the public health advice recommending abstinence and found that whilst some viewed this 
as responsible, others condemned it as a way of policing women. Authors concluded that the 
women in the study felt it was generally acceptable to drink responsibly while pregnant and 
supported their views by normalising occasional drinking and emphasising lower levels of 
consumption with lower risks. Similar findings have been reported by several other studies 
(Elek et al., 2013; Kesmodel & Schiøler Kesmodel, 2002; Meurk et al., 2014). 
 
From the perspective of healthcare professionals there can be a reluctance to ask or 
advise about PAU and, due to varying attitudes and level of knowledge of the guidelines and 
risks of PAU, different recommendations are often given to patients (Coons et al., 2017).  Not 
all healthcare providers routinely discuss alcohol use with women of childbearing age (Tough 
et al., 2005), or use validated screening tools (Wangberg et al., 2015). Midwives may be 
knowledgeable about the associated risks of PAU but may not always adhere to guidelines and, 
may lack the confidence to advise women about PAU (Payne et al., 2014). Other barriers 
include competing priorities, time constraints, inadequate skills or protocol and the relationship 
between women and their healthcare provider (Oni et al., 2019).  It is therefore not surprising 
that missed opportunities to identify PAU during the pre-conception phase and throughout 




PAU is a significant public health concern in the UK, and despite recommendations for 
abstinence, estimated rates remain high. A multitude of barriers exist when attempting to 
accurately obtain information about PAU, and doing this in a confidential, anonymous manner 
has been suggested in order to reduce reporting bias and support women in providing this 
information (Muggli et al., 2015). This study is the first of its kind in the UK to assess PAU in 
a large sample of self-selected women in such an anonymous manner.  
 
Furthermore, knowledge and attitudes are important determinants of health behaviour, 
however there is limited research exploring the impact of interventions on these in the context 
of PAU. Research has typically used change in maternal drinking behaviours as a measure of 
efficacy of preventative interventions (Ospina et al., 2011). Additionally, studies have 
predominantly recruited women with either reported PAU or those at high risk of PAU (Stade 
et al., 2009; Gilinsky et al., 2011; Ujhelyi Gomez et al., 2020), thus lacking generalisability to 
the wider population. This study aims to address these gaps by assessing the efficacy of an 
information leaflet in changing attitudes and knowledge towards drinking in a sample of 
pregnant, or recently pregnant, women.  By better understanding attitudes and knowledge of 
women towards drinking during pregnancy, recommendations for intervention research and 
clinical practice can be made. 
 
Objectives and research questions  
The following research questions were assessed: 
1. What is the prevalence of self-reported PAU in a self-selected sample of women in the 
UK?  
2. What are women in the UK’s attitudes towards, and knowledge of, the risks of PAU? 
3. Can an information leaflet have an impact on attitudes and knowledge towards PAU? 





This cross-sectional study implemented a quasi-experimental within-subjects pre and 
post-test design. An online self-administered anonymous questionnaire was developed and 




Inclusion criteria were women in the UK over the age of 18, who had been pregnant at 
any time since April 1st, 2016 or were pregnant at the time of participation (during the 
recruitment period July 20th, 2020 to December 31st, 2020). Participants had to be residing in 
the UK at the time of pregnancy and study completion and have sufficient English language 
literacy skills to complete the survey. Those who did not meet criteria or required additional 
support needs were excluded. The date of April 1st, 2016 was chosen as a cut-off point due to 
changes in policy and healthcare guidance on PAU in the UK. There was no restriction placed 
on whether it was the participants’ first pregnancy, and participants were advised to report on 
their most recent pregnancy if they had had more than one since April 2016.  
 
Procedure  
Recruitment took place online via social media platforms such as Facebook, Twitter, 
and LinkedIn. The study was advertised via an online poster (Appendix F) and promoted on 
various sites on these platforms, for example Facebook “Mums” and “Mums-to-be” groups. 
Appropriate agencies and organisations such as Mumsnet, National Childbirth Trust, Maternal 
Mental Health Alliance and FASD Network UK were also informed of the study and could 
choose to share details with members/followers on their webpages, forums, and social media 
platforms. Emails with the poster were sent to the above organisations on a monthly basis 
during the recruitment phase, which provided a description of the study and invited those 
interested to take part by following an electronic link to the study on Qualtrics. 
 
The Qualtrics link led first to the participant information sheet and then to the consent 
form. Following indication of consent, the participant was directed through the questionnaire, 
which was divided into various sections. The intervention i.e., an information leaflet was 
embedded in the questionnaire, and participants were instructed to read the leaflet (either in 
pdf form or on their web browser, dependent on their device) and following this return to the 
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questionnaire. On completion, a debrief page was provided and participants were informed that 
they could access a summary of the findings of the study on this webpage once completed in 
May 2021. The study was expected to take approximately 20 minutes and participants were 
given the option following the questionnaire to enter into a prize draw to win one of three £50 
Amazon Gift Cards. If they chose to enter, they were directed to another Qualtrics link. 
 
Ethical considerations 
Ethical approval was obtained by the DClinPsychol Ethics Committee within the 
University of Edinburgh (illustrated in Appendix B). No identifiable participant information 
was obtained in the survey and in order to protect respondent anonymity, an ‘Anonymous Link’ 
hyperlink was utilised before distribution, disabling the survey from collecting participants’ IP 
addresses. Details of the study and its voluntary nature were outlined in the participant 
information sheet and consent form (Appendices D & E).  
 
All information collected was stored securely on the Qualtrics platform, which is GDPR 
compliant. Opt-in to the prize draw was facilitated via an anonymous hyperlink, which was 
stored separately and not linked to survey responses. Although participants were unlikely to be 
considered vulnerable or exposed to harm whilst undertaking the study, information and 
support services were detailed at numerous points and links were provided should they wish to 





A bespoke questionnaire gathered information on participant’s age, ethnicity, marital 
status, employment status, level of education, and mental health status. Information on 
pregnancy was also captured including year of pregnancy, location of residency at the time, 




A screening question was utilised to ascertain whether the participant had ever 
previously consumed alcohol. Information on PAU was then captured using the Alcohol Use 
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Disorders Identification Test - Consumption (AUDIT-C; Bush et al., 1998), a 3-item screening 
tool for an estimation of alcohol consumption. This is a shortened version of the 10-item 
AUDIT measure (Saunders et al., 1993), validated for use in pregnant populations (Dawson et 
al., 2005) and recommended for guiding conversation on PAU (Murdoch Children’s Research 
Institute, 2010). It has robust psychometric properties and has been shown to demonstrate high 
levels of sensitivity (95%) and specificity (85%) in pregnant women (Burns, et al., 2010).  
 
AUDIT-C questions measure (1) the frequency of drinking, (2) the quantity of alcohol 
consumed on a typical day, and (3) the frequency of drinking ≥6 alcoholic drinks on one 
occasion. A total score is calculated to provide an indication of risks to the individual’s health 
and used as a brief screen for alcohol problems.  
 
The AUDIT-C was utilised twice; to capture levels of alcohol consumption prior to the 
participant finding out she was pregnant and following this during the pregnancy. For example, 
participants were asked: “Before you found out that you were pregnant, how often did you have 
a drink containing alcohol?” and “During your pregnancy, how often did you have a drink 
containing alcohol?”.  
 
A visual guide on what is one standard unit of alcohol (from www.drinkaware.co.uk) 
accompanied this measure. One further question asked if there had been a change in 
participants drinking habits after they found out they were pregnant.  
 
Attitudes and knowledge 
Attitudes and knowledge of PAU were assessed utilising a 12-item ‘Alcohol and 
Pregnancy Questionnaire’ (Peadon et al., 2011). This questionnaire was initially adapted from 
the Health Canada survey titled ‘Alcohol Use During Pregnancy and Awareness of Fetal 
Alcohol Syndrome’ which was utilised in a survey on 2724 Canadian women (Environics 
Research Group, 2006). Following modification and a pilot study, the measure was used in an 
Australian nationwide cross-sectional study of 1102 women aged between 18-45 years.  To 
date, psychometric data on this measure has yet to be published, but it remains the only measure 
of attitudes and knowledge towards PAU. Participants responded to these items on a 5-point 
Likert scale (from 1, Strongly agree, to 5, Strongly disagree). 
 
 78 
Additional items on knowledge of FASD and awareness of risks associated with PAU 
were also obtained from Peadon et al.’s (2011) study. Participants were asked to rate 7 items 
on a 5-point scale whether they thought drinking during pregnancy increased certain risks such 
as miscarriage or seizures. One question asking whether participants had heard of the term 
FASD was also included.  
 
Guidance on prenatal alcohol consumption  
Guidelines and recommendations from the UK’s CMO regarding alcohol consumption 
during pregnancy were extracted from the Department of Health’s ‘Alcohol Guidelines 
Review’ (2016). Awareness and attitudes towards these were ascertained by 4 questions 
designed by the research team. For example, participants were asked if they were aware of the 
guidance, how much they agreed with aspects of it on a 5-point Likert scale (from 1, Strongly 




The intervention comprised of an information leaflet known as ‘Alcohol and 
pregnancy’, developed by the Royal College of Obstetricians and Gynaecologists (2018). The 
information in this outlined the effects of prenatal alcohol consumption on a baby’s 
development in the womb and gave information about FASD and guidance on alcohol 
consumption during pregnancy (illustrated in Appendix G). 
 
Power calculation  
G* Power was used a priori to guide sample size calculations for pre and post analysis 
and multiple regression (Faul et al., 2007). A two-tailed approached with a medium effect size 
(d = 0.5) and alpha level of 0.05 indicated that a sample size of 57 would be required to detect 
differences using Wilcoxon signed-rank test. The minimum sample size for a multiple 
regression with 6 predictor variables, an alpha level of 0.05 and moderate effect size (f2= 0.15) 
was 146.  
 
As an objective of this study was to assess self-reported prevalence of PAU in the UK, 
prevalence data was also used to guide sample size calculations. Previous research has 
estimated prevalence rates at 40% for PAU in the UK (Popova et al., 2017), and the literature 
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proposes that for this rate, an appropriate sample size is 92 and 576 for moderate and very low 
margin errors, respectively (Hajian-Tilaki, 2011).  
 
Data analysis  
Statistical analyses were conducted using IBM SPSS Statistics (Version 25). 
Descriptive analysis of the sample was completed with the demographic variables listed above, 
self-reported prevalence of PAU, and attitudes and knowledge. A series of Wilcoxon signed-
rank tests were performed to assess the efficacy of the intervention on attitudes and knowledge 
towards PAU. Following this a multiple regression analysis was conducted to assess factors 
predictive of the changes in attitudes and knowledge following the intervention. Predictive 
variables were age, level of education, marital status, year of pregnancy, knowledge of CMO 
guidance on PAU and pre-attitude and knowledge scores. These were re-categorised (as 
depicted in Table 1) and dummy variables created for age, level of education and year of 
pregnancy as these were categorical in nature. Marital status was dichotomised into partner/no 
partner, and pre-attitude score was measured as a continuous variable.  
 
Data screening  
Data was screened to test that it met statistical assumptions. Due to the ordinal nature 
of the data, Wilcoxon-signed rank tests were conducted to determine the efficacy of the 
intervention. Cases with missing data were omitted and analyses conducted for full data sets 
only. Difference scores were approximately symmetrically distributed, as indicated by a 
histogram and Shapiro Wilk statistic of p = .94.   
 
Tests of skewness and kurtosis indicated that the data was not normally distributed for 
both pre- and post-intervention scores on the attitude and knowledge measure (z = 11.95 and z 
= 14.69 respectively). This was also observed by Shapiro Wilk’s test for normal distribution (p 
< .05). However, research indicates that larger sample sizes are likely to be overly sensitive to 
statistical tests of deviation, and minor deviations can produce significant p values (Uttley, 
2019). Given the W statistic was large for both pre- and post-attitude data (p = .94 and p = .92 
respectively), the deviation was considered to be minor and Wilcoxon Signed Rank tests were 
therefore completed.  
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Assumptions for parametric tests were met for multiple regression; independence of 
residuals was indicated by a Durbin-Watson statistic of .707, there was no evidence of 
multicollinearity as observed by tolerance values great than 0.1, values for Cook’s distance 
above 1, and visual inspection of a Q-Q plot indicated normality. Histograms and boxplots 
highlighted a violation of assumption of outliers. There were 13 outliers, as indicated by 





Overall, 1663 participants followed the link for the study and 1536 (92%) consented to 
take part. The typical respondent was 33.3 years of age (SD= 4.89), white (98%), married or 
cohabiting with a partner (92.4%) and had completed a bachelor’s degree or higher (73%). 




Demographic Characteristics of Participants  
Characteristic N % 
Age (n = 1456)   
19-25 90 6.2 
26-35 895 61.5 
36-50 471 32.3 
Ethnicity (n = 1468)   
White (UK) 1282 87.3 
White (Other) 160 10.9 
Other 26 1.8 
Marital Status (n = 1412)   
Married 970 68.7 
Co-habiting 335 23.7 
Other 107 7.6 
Employment Status (n = 1454)   
Employed Full-time/Part-time 942 64.8 
Maternity leave 323 22.2 
Student/Unemployed/Unable to work 189 13.0 
Highest qualification received (n = 1463)   
Standard grades/GCSE level or Highers 238 16.3 
Bachelor’s Degree or higher  1070 73.1 
Other 155 10.6 
Mental Health Status (n = 1468)   
Excellent  137 9.3 
Very good 407 27.7 
Good 456 31.1 
Fair 378 25.8 
Poor 90 6.1 
Location during pregnancy (n = 1463)   
Scotland 692 47.3 
England 555 37.9 
Wales 115 7.9 
Northern Ireland 101 6.9 
Year of pregnancy (n = 1467)    
Currently pregnant/2020 447 30.5 
2016-2019 1020 69.5 
Pregnancy (n = 1467)   
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Planned 1214 82.8 
Unplanned 253 17.2 
When found out about pregnancy (n = 1468)   
Within first 6 weeks 1351 92.0 
1st trimester  99 6.7 
2nd trimester 15 1.0 




The majority of the sample had consumed alcohol before (98%, n = 1331). Information 
on alcohol consumption prior to finding out they were pregnant and during their pregnancy 
was gathered using the AUDIT-C (illustrated in Table 2). UK standard units and scoring system 
were utilised, and participant’s scores were calculated as per recommended for use in clinical 
practice. Scores range from 0-12, with below 5 indicating “lower risk drinking” and 5+ 




Alcohol Consumption on the AUDIT-C Questionnaire at Two Time Points: Before 





Frequency of drinking  
 
(n = 1358) (n = 1356) 
Never 52 (3.8%) 1014 (74.8%) 
Monthly or less 379 (27.9%) 289 (21.3%) 
2-4 times per month 497 (36.6%) 46 (3.4%) 
2-3 times per week 347 (25.6%) 7 (0.5%) 
4+ times per week 83 (6.1%)  0 (0%) 
Quantity consumed on typical day of drinking in 
standard UK units 
(n = 1358) 
 
(n = 1357) 
0 161 (11.9%) 1061 (78.2%) 
1-2 431 (31.7%) 288 (21.2%) 
3-4 382 (28.1%) 5 (0.4%) 
5-6 215 (15.8%) 2 (0.1%) 
7-9 103 (7.6%) 1 (0.1%) 
10 or more 66 (4.9%) 0 (0%) 
 
Frequency of heavy episodic drinking (6 or more 
units per occasion) 
  
(n = 1357) 
 
(n = 1357) 
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Never 240 (17.7%) 1343 (99.0%) 
Less than monthly 681 (50.2%) 11 (0.8%) 
Monthly 277 (20.4%) 1 (0.1%) 
Weekly 155 (11.4%) 2 (0.1%) 
Daily or almost daily  4 (0.3%) 0 (0%) 
Audit Score  
 
(n = 1357) (n = 1354) 
<5 (“lower risk drinking”) 833 (61.4%) 1351 (99.8%) 
5+ (further screening required) 524 (38.6%) 3 (0.2%) 
Note. “Before” refers to alcohol consumption before women found out about the pregnancy, and could 
represent consumption prior to or following conception.   
 
A reduction in the frequency and quantity of alcohol consumed and frequency of binge 
drinking was observed from “before they found out they were pregnant” to “during their 
pregnancy”. AUDIT-C scores also reduced; the mean score before finding out about the 
pregnancy was 4.11 (SD=2.19, Mdn = 4.0), and during pregnancy was 0.32 (SD= 0.64, Mdn = 
0.0).  
 
Women were also asked about changes to their alcohol consumption when they found 
they were pregnant. The majority of participants stopped drinking alcohol completely (n = 981, 
78.7%) and a further 204 (16.4%) continued to drink on special occasions only. Only three 
participants (0.2%) reported they continued “to drink the same amount as before”, no 
participants increased intake and 4.7% reduced their intake.  
 
Impact of intervention  
Attitude and Knowledge 
1331 participants provided responses to the ‘Attitude & Knowledge Towards Drinking 
During Pregnancy Scale’ prior to the intervention and 1120 post-intervention, an attrition rate 
of 16% (n = 211).  
 
To assess differences between pre and post scores following the intervention responses 
to all 12 statements were collated and scored to provide total scores and means. Statements 3 
and 4 were re-coded in order for the dataset to point in the same direction across items and 
scores ranged from 12 (negative attitude) to 60 (positive attitude). Of the 1120 participants, 
47% (n = 527) responded more negatively towards PAU following the intervention, whilst 
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there were no differences in attitudes for 29% (n = 326). A Wilcoxon signed rank-test 
determined there was a statistically significant median decrease in positive attitudes towards 
drinking following the intervention (Mdn = 16) compared to attitudes prior to the intervention 
(Mdn = 17) with a small effect size, z = -9.67, p < .001 r = 0.29. This is illustrated below in 









Note. Scores range from 12-60, with lower scores indicating more negative attitudes towards 
PAU. 
 
The majority of participants demonstrated negative attitudes towards PAU, which 
increased following the intervention. For example, four out of 5 participants agreed that 
pregnant women should not drink alcohol (81.5%) pre-intervention, which increased to 89.6% 
post-intervention. 8.6% of women disagreed with this statement prior to the intervention, 
compared to 5% post-intervention. Secondly, more participants reported stronger 
agreement/disagreement with statements following the intervention. For example, more 



























intervention than before (79.3% and 68.0% respectively). Pre and post scores are illustrated 




Pre- and Post-intervention Individual Scores on the ‘Attitude and knowledge Towards Drinking in Pregnancy’ Scale  
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Knowledge of risks of PAU and guidance  
 The majority of participants had heard of the term Foetal Alcohol Spectrum Disorder 
(see Figure 3), and were aware of the CMO’s guidance (85.5%, n = 1130). When asked to 
respond to the following item: “There is no safe amount of alcohol during pregnancy. Do you 
feel that this message is widely known throughout the UK?”, 37.2% of participants reported 










 Several Wilcoxon signed-rank tests were conducted to determine differences in 
knowledge post-intervention. Difference scores were approximately symmetrically distributed, 
as assessed by visual inspection of histograms on each item. Table 3 below illustrates scores 

















Knowledge of Effects of PAU and Level of Agreement with UK CMO’s Guidance  









Mdn Z r 
PAE increases risks of:        




1.0 -18.05*** 0.54 






1.0 -8.8*** 0.27 




1.0 -12.1*** 0.37 




2.0 -11.7*** 0.35 
5. Birth 
defects/malformations 
1095 1.77(0.79) 2.0 1.38 
(0.64) 
1.0 -15.5*** 0.47 




1.0 -17.3*** 0.52 
Agreement with guidance 





1.0 -10.3*** 0.31 






1.0 -9.5*** 0.28 
*** p < .001 
Note. Response options were 1 (strongly agree), 2 (agree), 3 (neither agree nor disagree), 4 (disagree), 




 Significant differences were observed between pre and post intervention on all items 
assessing knowledge of risks associated with PAU and level of agreement with the UK CMO’s 
guidance. Effect sizes ranged from moderate to large as indicated by r (Cohen, 1988; Fritz et 
al., 2012).  
 
 An increase of 7.5% was observed for agreement with the guidance that there is no safe 
level of alcohol use during pregnancy following the intervention, and 5.8% fewer disagreed 
with this post-intervention. Additionally, there was a 9.1% increase in those who strongly 
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agreed with the guidance that women should avoid alcohol during pregnancy post-intervention, 
and a 3.9% decrease in those who disagreed with this statement (from 11.2% to 7.3%).  
 
 Participants agreed more strongly with statements of risks associated with PAU 
following the intervention. For example, there was a statistically significant increase of 32.9% 
in those who strongly agreed that PAU increases the chance of miscarriage, and a decrease in 
those who disagreed from 6.1% to 1.8% following the intervention. Large effect sizes were 
observed particularly for this and lower IQ. This shift in knowledge was observed across the 










Factors predictive of change  
A multiple regression was conducted to explore whether demographic variables 
predicted the differences observed in attitudes and knowledge following the intervention. The 
model predicted statistically significant change scores in attitude and knowledge with a 
medium effect, F (12, 1047) = 25.838, p < .001, adj. R2 = .22. Regression coefficients and 






Multiple Regression Results for Change Scores in Attitudes and Knowledge  
Change Score B 95% CI for B 
LL              UL 




Model      .23 .22** 
Constant 4.127 3.143 5.111 .502    
Age (36-50) [Reference category]     
Age (19-25) .472 -.238 1.183 .362 .039   
Age (26-35) -.066 -.389 .257 .165 -.012   
Postgraduate Education [Reference category]   
Education 
(Standard/Highers) 
-.211 -.662 .239 .230 -.029   
Education (Bachelor’s 
Degree) 
-.525 -.861 -.188 .172 -.094*   
Education (Other/trade) -.864 -1.376 -.352 .261 -.097*   
Year of pregnancy (2019) [Reference category]  
Year of pregnancy (2020) .230 -.142 .602 .190 .039   
Year of pregnancy (2018) .248 -.172 .668 .214 .037   
Year of pregnancy (2017) .361 -.152 .874 .261 .042   
Year of pregnancy (2016) -.044 -.591 .502 .278 -.005   
Marital status .371 -.231 .972 .307 .034   
Knowledge of CMO 
guidance 
.012 -.406 .430 .213 .002   
Pre-attitude and knowledge 
score 
-.293 -.327 -.259 .017 -.465**   
Note. Model = “Enter” method in SPSS Statistics Version 25. B = unstandardised regression 
coefficient; CI = confidence interval LL = lower limit; UL = upper limit; SE B = standard 
error of the coefficient; β = standardised coefficient; R2 = coefficient of determination; Adj. 
R2 = adjusted R2.  
As ‘age’, ‘education’ and ‘year of pregnancy’ were categorical variables, these were dummy 
coded. ‘Age (36-50)’, ‘postgraduate education’ and ‘year of pregnancy (2019)’ were 
reference groups.  
*p < .01. **p < .001 
 
Results illustrated that education (Bachelor’s degree or other/trade qualification) and 
initial score on the measure explained significant proportions of variance in the change score. 
Those who scored higher on the measure i.e., who already had more negative attitude towards 
PAU were predicted to have a lower change score.  
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Following analysis of the output and closer inspection of results, multicollinearity was 
suspected within the dummy variables. A further comparison of the same dataset was therefore 
conducted utilising a stepwise regression model to assess which factors contributed the most 




Stepwise Regression Results for Change Scores in Attitudes and Knowledge 




Model 1    .23 .23*** 
   Constant 5.105 .377    
   Pre-attitude and knowledge score -.332 .021 -.476***   
Model 2    .23 .23* 
   Constant 5.036 .377    
   Pre-attitude and knowledge score -.338 .021 -.484***   
   Post-graduate education  .432 .180 .071*   
Model 3    .23 .23* 
   Constant 4.273 .539    
   Pre-attitude and knowledge score -.339 .021 -.487***   
   Post-graduate education .470 .181 .078*   
   Marital status .730 .369 .059*   
Note. Model = “Stepwise” method in SPSS Statistics Version 25. B = unstandardised regression 
coefficient; CI = confidence interval LL = lower limit; UL = upper limit; SE B = standard error 
of the coefficient; β = standardised coefficient; R2 = coefficient of determination; Adj. R2 = 
adjusted R2.  
*p < .05, **p < .01. ***p < .001 
 
The most significant predictor to emerge was the pre-intervention score on the attitude 
and knowledge scale accounting for 23% of the variance of the model [F (1, 880) = 258.33, p 
< .001, adj. R2 = .23]. Having a post-graduate education and marital status also contributed 
significantly to the model [F (2, 879) = 132.73, p < .05, adj. R2 = .23.] and [F (3, 878) = 90.08, 




Main findings  
This study provides contemporary national data from a self-selected sample of women 
in the UK on the prevalence of alcohol consumption in pregnancy, and their attitudes and 
knowledge of the risks associated with PAU. It also explores the impact of an educational 
intervention on attitudes and knowledge.  
 
Data on the prevalence of alcohol consumption highlights several points of interest. 
General alcohol consumption in the sample was high and the majority of women (82%) 
reported heavy episodic drinking prior to recognition of pregnancy. This is higher than rates of 
pre-pregnancy binge drinking observed by other studies.  A cross-cohort comparison of multi-
centre population-based studies conducted by O’Keeffe et al. (2015) illustrated prevalence 
rates of 59% in the Irish ‘SCOPE’ study and 24% in the multicentre ‘PRAMS’ study, although 
the criteria used in these studies is not clear. Additionally, a significant proportion of women 
in this study (39%) scored above the threshold (≥ 5) on the AUDIT-C for ‘high risk of harm’, 
indicating their consumption was at a harmful level for their health, and their baby’s health, if 
in the early stages of pregnancy. Further screening and targeted prevention such as a referral 
to specialist alcohol services would have been prompted as a result of these scores, regardless 
of whether they were pregnant.  
 
A marked decline in consumption following recognition was observed and is consistent 
with the patterns noted in the literature; namely that a peak in binge drinking is observed around 
the period of conception which then reduces to a low level at the time of recognition 
(Kesmodel, 2001). Three out of four women reported ‘never’ drinking alcohol during 
pregnancy, and 99% reporting no binge drinking. This abstinence or significant reduction in 
PAU following recognition mirrors previous studies across countries including Scotland 
(Wolfson, 2018), Australia (Cameron et al., 2013; McCormack et al., 2017), and Canada 
(Tough et al., 2006). Despite this trend in consumption, research has indicated prevalence rates 
of PAU to be approximately 40% using self-reported measures (O’Keeffe et al., 2015) and 
biological markers and (Popova et al., 2017). In this study 25% of women continued to drink 
during pregnancy following recognition. Additionally, 21% reported drinking monthly or less, 
and reported consuming a quantity of 1-2 units on a ‘typical day of drinking’. Although these 
rates are lower, they emphasize that PAU remains a concern in women in the UK even in a 
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sample that is predominantly comprised of women who were married, had high levels of 
education and had planned their pregnancy. 
 
Findings on attitudes and knowledge towards PAU were encouraging. The majority of 
women in this study held negative attitudes towards PAU and were in agreement with the UK’s 
CMO’s guidance that pregnant women should not drink alcohol even before exposure to a 
leaflet on the subject. This is in accordance with qualitative research, which has demonstrated 
support for this abstinence message, although has iterated that endorsement of such a message 
does not necessarily equate to its adherence (Holland et al., 2016). Moreover, nearly all women 
disagreed that it was okay for pregnant women to become intoxicated and concurred that PAU 
carried risks to the foetus, as also observed by Esposito et al. (2015). Additionally, most women 
agreed that health professionals should ask pregnant women about their alcohol consumption. 
Although most women agreed that PAU carried risks, this did not necessarily translate to 
specific knowledge about FASD or the UK CMO’s guidance. In this study, 82% of women had 
heard of FASD, slightly less than that observed in a Canadian survey where 88% had heard of 
FAS/FASD (Environics Research Group, 2006). A further 15% had not heard of the UK 
CMO’s guidance on PAU, and two out of five women reported that they felt the message of 
abstinence was not widely known throughout the UK. This indicates a need for further public 
health campaigns to raise awareness of the risks throughout our society. 
 
The intervention employed had a positive impact on attitudes and knowledge. Although 
attitudes of women in this study towards PAU were predominantly negative, significant 
positive changes were observed as a result of the information leaflet. Women were significantly 
more knowledgeable about the specific risks associated with PAU and a larger proportion of 
women were in agreement with the UK’s guidance on abstinence following the intervention. 
Additionally, attitudes shifted from more neutral standpoints to stronger disagreement with 
PAU. Pre-existing attitudes, knowledge and education were factors predictive of these changes, 
as those with less negative attitudes were more likely to experience change following the 
intervention. Results were subtle but promising and provide support for the utility of education 
interventions in general populations and suggest that those with more impartial views may gain 
more benefit.  
 
Explanations of this impact on attitudes and knowledge can be drawn from health 
behaviour literature. As mentioned previously, information regarding health consequences is 
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an effective BCT for reducing PAU (Fergie et al., 2019). Furthermore, knowledge, personality, 
attitudes, beliefs, habits, social circumstances and norms are all motivators of health behaviour 
(Morrison & Bennett, 2009), and as knowledge influences attitude, this results in a change to 
health behaviour. Although this study did not assess direct behaviour change, it did 
demonstrate significant changes in attitudes and knowledge of risks and adds to the literature 
of intervention research in this area.  
 
Strengths and limitations  
A key strength of this study is its large sample size and national recruitment of women 
across the UK.  It provides novel information on self-reported prevalence of PAU in the UK 
and on the role of an educational intervention on attitudes and knowledge towards PAU. 
Furthermore, its anonymous nature and use of validated questionnaires to assess prevalence is 
likely to have facilitated more transparent and accurate reporting of PAU, thus hoping to 
mitigate risks of reporting and measurement bias.  
 
This study is not without its shortcomings, however. Firstly, the representativeness of 
the sample is a limitation that must be considered. The majority of respondents were white 
married women, with high levels of education and predominantly negative attitudes towards 
PAU. Populations of younger women, women of different ethnic origins, those in lower SES 
groups and with lower levels of education were underrepresented in this study. The average 
age of the sample was 33.3 years, which is higher than the average age of mothers in England 
and Wales (30.7 years) as recorded in 2019 (Office for National Statistics, 2019), and in 
Scotland (31 years in 2018) (The Scottish Public Health Observatory, 2020). Alongside 
homogeneity of the sample, 83% of women in this study reported their pregnancies as planned 
and had found out about their pregnancy in the first 6 weeks. This is disproportionate to national 
data, which indicates that in the UK over 40% of pregnancies are unplanned (Rudd et al, 2013), 
and consequently, these findings may lack generalisability to other populations, even within 
the UK.  
 
Secondly, the methodology of the study has its limitations. The most common method 
of measuring PAU is via maternal self-reports; however, research has consistently 
demonstrated these are likely to underestimate prevalence rates (Howlett et al., 2018; Lange et 
al., 2014; McQuire et al., 2019). PAU is an emotive and sensitive topic, and unsurprisingly 
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social desirability bias, recall bias and use of complex and subjective language are all existing 
barriers to accurate self-reporting in cross sectional studies (Muggli et al., 2015). This study 
attempted to mitigate these risks via anonymous recruitment, however these factors must be 
considered. It is also possible that drinking behaviour influenced participants’ decision to take 
part in the study as women with heavier PAU may be less likely to participate, resulting in 
disproportionate prevalence estimates and less diverse attitudes and knowledge. In addition to 
this, despite recruiting a large sample size, the risk of this study being overpowered must be 
considered. The probability of Type 1 errors increase with larger sample sizes as there is more 
potential for effects with small statistical significance to be detected (Lenth, 2001). Results of 
the intervention, more specifically effect sizes observed between pre, and post intervention 
scores should therefore be interpreted with caution.  
 
Furthermore, due to the phrasing of questions, conclusions regarding PAU prior to 
recognition of pregnancy are limited. This study asked women about consumption during 
pregnancy and before they found out they were pregnant. This phrasing, “before you found out 
you were pregnant” could have been improved to ensure women were retrospectively reporting 
on consumption during the period in which they had conceived but were not yet aware of the 
pregnancy. Thus, any conclusions drawn based upon risks of associated PAU at the first time 
point are limited and could represent consumption either before or after conception. As the data 
can only conclude about PAU following recognition, this may have driven down prevalence 
rates. Results may have also led to different conclusions dependent on the method of analysis 
employed. Subgroup analysis by the year of pregnancy in which women reported  and, whether 
women consumed alcohol during pregnancy or not, could have led to different results on the 
efficacy of the intervention. Sensitivity analyses could therefore have been performed on such 
subgroup analyses in order to assess if findings would have remained consistent with those 
found and if so, strengthen the conclusions drawn on intervention effects.  
 
Clinical implications and future research  
Educational interventions such as the one used in this study appears to hold promise in 
changing attitudes and improving knowledge of the risks of PAU and thus should be regarded 
as appropriate interventions for general populations. Ease of delivery, cost-efficacy and 
equitability are some of the major advantages of such interventions, which can be delivered in 
multiple formats (online/paper/face to face/postal) and across a variety of settings. Whilst 
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online delivery of interventions offers considerable advantages, the question as to whether 
online surveys can reach representative samples must be considered. More extensive research 
investigating the efficacy of such interventions across a range of cohorts including younger 
women of childbearing age, substance misuse populations and ethnic minorities is 
recommended. In addition, given the patterns observed across studies of high level of 
consumption in pre-conception stages, efforts of healthcare professionals should be targeted 
towards women of childbearing years and not just pregnant women, to reduce risk of 
inadvertent exposure at an earlier stage and subsequently, the prevalence of FASD.  
 
Interestingly, the results of this study may offer some insight into the mechanisms by 
which educational or public health interventions for PAU and FASD operate. More 
specifically, results of the exploratory regression indicate that attitude and knowledge were the 
most significant predictors of change following the intervention, thus pointing towards a need 
for an educational and preventative focus of interventions aimed at reducing risk of FASD. 
Consideration of timing of implementation may also be important, as earlier education of risks 
of PAU as in secondary schools may be more protective against future use of alcohol. Universal 
preventative school-based interventions on alcohol use amongst adolescents has been shown 
to have small but positive effects, with possible longer term health gains (Strøm et al., 2014). 
Social determinants of health are therefore likely to be important factors impacting the efficacy 
of preventative educational interventions, and further research exploring these is warranted.  
Conclusion 
This study is the first of its kind to assess PAU in a self-selected sample of women in 
the UK, and the impact of an education intervention on attitudes and knowledge of risks. 
Findings identified that although the level of consumption was low, 25% of women continued 
to drink during pregnancy. The information leaflet had a positive impact and findings provide 
support for the utility of brief educational interventions in increasing knowledge of harm 
caused by prenatal alcohol consumption and reducing positive attitudes towards PAU. 
Implementation of such interventions at community and clinical levels could reduce PAU in 
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Section 1: Introduction 
1.1 Provide a brief critical review of relevant literature, which should clearly demonstrate the 
rationale and scientific justification for the research 
1000 – 1500 words 
Relevant to IRAS A12 
Alcohol use in Scotland  
Alcohol consumption is a major health, economic and social burden in Scotland, with reports from 
the Scottish Government indicating costs of £3.6 billion each year in health, social care and crime 
related services (York Health Economics Consortium, 2010). The Scottish Health Survey 
conducted in 2017 stated that one in four adults are consuming alcohol at potentially hazardous 
levels (>14 units per week), and one in six women (McLean et al., 2018). There has been a steady 
rise in consumption over the past two decades, and this is thought to be associated with lower costs 
of alcohol, increased choice and easier accessibility, and a shift in cultural attitudes.  
 
Despite alcohol consumption being an integral part of Scottish culture, level of alcohol use is often 
underreported. This might be related to a general lack of knowledge about the units within drinks 
and/or social pressures to drink. For example, Sharp et al.’s study in 2014 assessed 1,492 Scottish 
adults’ perceptions of alcohol use. Results highlighted that half of participants were unable to 
identify the correct number of units in a pint of beer, spirit or a glass of wine, and 41% reported 
that others would think they were odd if they did not drink at all. Furthermore, the Scottish Health 
Survey in 2015 identified that adults self-reported 20.8 units of alcohol per week, exceeding the 
recommended guidelines of 14 units per week. However, these figures only accounted for 55% of 
total alcohol sales. This renders the question whether Scottish adults are aware of the amount they 
are consuming, or if they underreport the amount on alcohol screening instruments.   
 
Underreporting of alcohol consumption during pregnancy is a particular public health concern and 
may be related to the stigma associated with alcohol use during pregnancy. There is relatively little 
research in this area which could be reflective of the challenges associated with reliable data 
collection and methodology employed. Some measures appear to be more effective than others in 
identifying alcohol use, for example self-administered questionnaires have been found to be more 
sensitive than questionnaires administered by an interviewer in identifying alcohol consumption 
(Witte & Haile, 1996). Czeizel et al. (2004) investigated the reliability of self-reported information 
in mothers of children with congenital abnormalities and found low levels of reliability of self-
reported information regarding both smoking and alcohol use during pregnancy. This was felt to be 
due to feelings of guilt and shame, as mothers were concerned of the associations between their 
alcohol use and smoking and their child’s condition. This reporting bias however was not observed 
in mothers of children without congenital abnormalities who reported more regular alcohol 
consumption during pregnancy. Public health prevention initiatives often utilise public awareness 
campaigns such as alcohol warning labels, which can inadvertently increase the stigma and blame 
associated with alcohol use during pregnancy (Bell et al., 2015).  
 
Prenatal alcohol use  
A study recently published in the Lancet indicated that the UK has one of the highest estimated 
prevalence of alcohol consumption during pregnancy across the globe at 41.3% (Popova et al., 
2017). Factors which might be related to this are inconsistencies in medical guidelines and 
 117 
discrepancies between countries as to safe levels of alcohol during pregnancy. Scottish guidelines 
had not been revised since 1995 when they were updated on April 1st, 2016 (Alcohol Focus 
Scotland, 2018). The consensus prior to 2016 was that minimal units were not harmful during 
pregnancy and guidelines recommended that pregnant women avoid alcohol for the first 3 months, 
and that “they should drink no more than 1-2 UK units once or twice a week” (NICE, 2008). 
However current Chief Medical Officer’s guideline states that no level of alcohol is safe during 
pregnancy, and that in order to reduce risks to the unborn baby “the safest approach is not to drink 
alcohol at all” (Department of Health, 2019). The Scottish Government launched a public 
awareness campaign around this time known as “No Alcohol No Risk” in an aim to discourage 
prenatal alcohol use and raise awareness of risks (WHO, 2016).  
 
 
The use of alcohol during pregnancy, otherwise known as ‘prenatal alcohol use’ (PAU) is the only 
direct cause of Foetal Alcohol Syndrome (FAS) or Foetal Alcohol Spectrum Disorder (FASD).  
FASD is the nondiagnostic umbrella term used to describe the constellation of impairments that 
result from PAU (Peadon & Elliott, 2010). Research on the impact of alcohol on the developing 
brain of an unborn baby has only recently been investigated so widely and the global prevalence of 
FASD is estimated to be 7.7 per 1000 children in the general population (Lange et al., 2017). 
Studies from Europe and the USA estimated prevalence rates of FASD varying from 1% to 10% of 
children in the general population (Roozen et al., 2016) (May et al., 2018). More specifically, 
recent research has proposed that up to 17% of children in the UK are believed to have symptoms 
consistent with FASD (McQuire et al., 2018).  
 
Children with FASD present with cognitive symptoms including difficulties with executive 
functioning, attention, memory, communication and sensory/motor impairments. Furthermore, it is 
associated with challenging behaviour, impairments in academic and social skills, and adolescents 
with FASD are 19-40 times more likely than the general population to be involved in the criminal 
justice system (Popova et al., 2011). As alcohol consumption is still prevalent during pregnancy for 
numerous reasons, it is not surprising that there are a growing number of children in Scotland with 
FASD and alcohol related neurodevelopmental deficits. The prevalence of FASD and PAU in 
Scotland is unclear however, and this has been a key area of focus for the Scottish Government 
over the past 2 years. A recent study in Glasgow investigated the prevalence and patterns of alcohol 
use during pregnancy through measurement of meconium levels in pregnant women. Researchers 
confirmed that alcohol consumption during pregnancy is underreported and identified that at least 
15% of women were consuming significantly harmful amounts of alcohol during pregnancy 
(Abernethy et al., 2018). 
 
Challenges 
There are numerous challenges with conducting research in this area, one such being the stigma 
associated with PAU and underreporting of level of consumption. Pregnant women often 
experience negative judgement from service providers if they disclose alcohol consumption (Poole 
& Isaac, 2001) causing significant barriers in seeking and obtaining the support they need (Green et 
al., 2016). Changes in guidelines surrounding PAU and lack of awareness of these, as well as the 
current culture of alcohol use have further hindered preventative work in the area. Screening 
methods utilised by healthcare professionals in clinical practice often make mothers feel as though 
they will be perceived negatively by others or accused of causing harm to their unborn child. This 
exacerbates the difficulties surrounding diagnoses of FASD, and results in lack of service provision 
as children are not being identified or supported. Further research is necessary on screening 
measures which will encourage transparent disclosure about PAU in order to identify children at 
risk of FASD or neurodevelopmental difficulties as a result of PAU.   
 
Rational for this study  
The literature has recommended the need for more effective prevention strategies targeting PAU 
and for monitoring of children born with FASD (Popova et al., 2017). A guideline proposed by the 
Scottish Intercollegiate Guidelines Network in 2016 highlighted that research on FASD should be a 
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high priority, and that because PAU is common across the general population in the UK, the focus 
should be on altering drinking behaviours at a population level. Recommended strategies include 
increasing awareness of new guidelines via social marketing campaigns, clearer warning labels on 
alcoholic drinks, and training healthcare professionals, healthcare workers and criminal justice 
workers to discuss alcohol consumption with women who are pregnant or seeking advice on 
conception (Alcohol Focus Scotland, 2017).  
 
Research on alcohol consumption during pregnancy in the general population both globally and in 
Scotland is limited. Studies have investigated stigma around alcohol consumption during 
pregnancy, however this has been from the perspective of healthcare professionals rather than the 
views of biological mothers (Payne et al., 2005). The proposed study aims to address this gap in the 
literature by investigating the prevalence of alcohol use during pregnancy in Scottish women, and 
factors associated with this. It aims to explore factors relating to the underreporting of alcohol 
consumption and assess perceptions of current screening tools used in clinical practice. As this will 
be conducted via an online anonymised questionnaire, it is hoped that stigma related to alcohol use 
during pregnancy will be significantly reduced, which will allow the prevalence of PAU to be 
assessed more transparently. This study aims to highlight the need to target this population at a 
service level in order to enhance our knowledge about alcohol consumption during pregnancy, 
identify possible high-risk groups, and make recommendations for healthcare screening and 
treatment plans. 
 
Section 2: Research Questions / Objectives 
2.1 What is the principal research question / objective? 
IRAS A10 
What is the prevalence of alcohol consumption during pregnancy in a sample of women in Scotland 
and what are the factors associated with higher levels of consumption? 
2.2 What are the secondary research questions / objectives, if applicable? 
Keep these focused and concise, with a maximum of 5 research questions 
IRAS A11 
Is lack of awareness of current guidelines on alcohol consumption associated with higher levels of 
alcohol use during pregnancy? 
Do women feel comfortable answering questions on alcohol consumption using current screening 
tools? 
Are there particular questions used to screen for alcohol consumption during pregnancy which 
would elicit more accurate responses? 
Is lack of disclosure or underreporting of alcohol use during pregnancy associated with perceived 
levels of stigma and/or feelings of shame/guilt? 
 
Section 3: Methodology 
3.1 Give a full summary of your design and methodology 
It should be clear exactly what will happen at each stage of the project 
IRAS A13 
Design 
This study will employ a cross-sectional, correlational within-groups design. Participants will be 
asked to complete an online questionnaire. The dependent variable will be alcohol consumption 
during pregnancy, as measured using the AUDIT-C questionnaire. The 7 independent variables of 
interest include demographic factors such as age, socio-economic status, marital status, level of 
education of alcohol guidelines, employment status, level of engagement with prenatal services, 




Ethical approval will be obtained from the Psychology Research Ethics Committee at the 
University of Edinburgh and from NHS Research Ethics Committee via IRAS.  
 
Participants & recruitment  
In order to gain a sufficient sample size, recruitment will take place across multiple platforms 
online. It aims to recruit women in the Scottish population over the age of 18 who have been 
pregnant within the previous 10 years. As recommended alcohol guidelines changed in April 2016 
this study aims to capture women who have been pregnant before and after this change. 
Participants must have been in contact with their GP or prenatal services with regard to the 
pregnancy.  
 
The study intends to recruit a representative sample of the general population as well as those with 
alcohol difficulties by targeting a range of settings. The study will be advertised via leaflets which 
will be displayed in multiple locations such as waiting rooms in GP practices, maternity health care 
services and children’s centres. An electronic link to the study will be provided on these leaflets, as 
well as information on the study. It will also be promoted through social media platforms such as 
Facebook, Twitter & LinkedIn, and other online organisations relevant to the study such as 
Mumsnet.  
 
There are certain caveats and ethical considerations of online recruitment to be noted. For example, 
some online pages such as Facebook groups which are freely accessible to the public may not have 
a moderator to seek permission from to advertise the study. In this circumstance the trainee will 
promote transparency and be forthright about their access to the group as a researcher. Permission 
will be sought to advertise the study from sites where a moderator is available and will comply with 
the sites’ policies and ‘terms of use’.  
 
The trainee will inform members within their health board of the study in order to enhance 
recruitment. Third sector support services such as Alcohol Focus Scotland and alcohol services in 
the trainee’s health board will also be contacted to inform them of research being undertaken and 
will be posted leaflets to the study which will be placed on noticeboards if permitted.  
 
Procedure 
The study will be advertised on leaflets and online platforms and participants will be instructed to 
follow or enter a link using an Internet browser on their device should they wish to conduct the 
study. This will direct them to the Qualtrics platform. In order to protect respondent anonymity, the 
‘Anonymous Link’ hyperlink will be employed before distributing the survey which disables the 
survey from collecting participants IP address.  
 
Firstly, participants will be directed to an information sheet outlining the rationale for the study and 
what it will involve. Informed consent will be gained by asking the participant to click on a 
checkbox if they wish to undertake the study before continuing, and subsequently will be directed 
to the questionnaire. Demographic information will be gathered using a questionnaire which will be 
designed specifically for the study. Items will be replicated from the Scottish Public Health 
Observatory surveys on alcohol use and health behaviours in the general public.  
  
Participants will then be required to complete questions regarding their knowledge of current UK 
drinking guidelines and guidelines specific to pregnancy. They will also be asked about perceived 
stigma from others when reporting alcohol consumption. Their perceptions of current screening 
tools such as the CAGE, T-ACE & TWEAK will then be assessed. Following this, the AUDIT-C 
will be administered to measure self-reported levels of alcohol use during pregnancy. Participants 
are permitted to withdraw from the study at any point by closing the internet browser they are 
using. They will be given a choice to save any responses made so additional but incomplete data 
can also be collected. This will be detailed in the information sheet.  
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Once participants have completed the questionnaire, they will be directed to a debrief form which 
will provide relevant contact details should the participant wish to contact other services for 
information or support following the study. Details of how they can access the findings of the study 
in the future will be provided, and participants will be given the option of providing their email 
address should they wish to be contacted with the results of the study once available.  
 
The questionnaire will be designed to maximise the data gathered and minimise participant burden 
and so it is estimated that the study will take 15 minutes to complete. Prior to any recruitment it 
will be piloted amongst 5-7 individuals to ensure there are no complications with the questionnaire 
in terms of its structure or wording of questions.  
 
Data storage 
Participants who have completed the study will be assigned a number on the survey platform. 
There will be no identifiable information as the study is anonymous and all data collected will be 
gathered on the survey software (Qualtrics). Data will be stored in a single secure data centre on 
this platform which is GDPR compliant. Access to the database will be permitted only for the 
trainee and supervisors involved in the study. On completion of the recruitment phase, data will be 
transferred to an Excel database which will be stored on and NHS network drive, which is backed 
up daily, as well as the University’s SharePoint system. The folder it is contained in will be locked 
and permitted for use by the trainee and supervisors involved. Once the study has been completed, 
all data held on Qualtrics and on NHS/University shared drives will be deleted.  
 
3.2.1 In which aspects of the research process have you actively involved, or will you involve, 
patients, service users and/or their carers or members of the public? 
Highlight as appropriate. 
IRAS A14-1 
Design of the research Analysis of results 
Management of the research Dissemination of findings 
Undertaking the research None of the above 
3.2.2 Give details of involvement, or if none, please justify the absence of involvement 
 
Participants will be involved in conducting the research study and providing data to address the 
research questions. They will also be involved in the dissemination of its findings should they 
choose to provide their contact details following a debriefing form.  
 
A poster of the study and its results will be presented at NHS departmental conferences and may be 
placed across relevant venues such as clinic waiting areas in GP surgeries, maternity health care 
centres, and third sector organisations such as Alcohol Focus Scotland.  
3.3 List the principal inclusion and exclusion criteria 
IRAS A17-1 and IRAS A17-2 
 
Inclusion: 
- Females over the age of 18 who have been pregnant or are currently pregnant, and have 
had contact with health care professionals regarding their pregnancy 
- Have proficient English abilities to enable them to complete the questionnaires  
 
Exclusion: 
- Females who have never been pregnant or who have not had contact with NHS services or 
healthcare professionals in relation to a pregnancy 
- Individuals who do not provide informed consent  
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3.4 How will data be collected? 
If quantitative, list proposed measures and justify the use of these measures. If qualitative, explain 
how data will be collected, giving reasonable detail (don’t just say “by interviews”.) 
 
Data will be collected via an online questionnaire. Demographic information will be collected at 
the beginning of the study and will gather the following information: 
- Age 
- Nationality 
- Marital status 
- Employment status 
- Year of pregnancy 
- Socio-economic status 
- Level of education 
- Previous history of mental health and/or substance use difficulties 
- Level of engagement with prenatal services  
 
Participants will then complete a questionnaire assessing their knowledge of recommended 
guidelines of alcohol use and units in beverages. They will be asked about the information they 
remember being given during their health checks, for example if they were given advice on dietary 
supplements such as folic acid, and advise on exercise, alcohol consumption and smoking. They 
will be asked about whether they may underreport alcohol use for reasons such as perceived stigma 
from others, lack of knowledge of standard units or guidelines, or due to memory difficulties 
caused by alcohol use. 
 
Subsequently participants will be asked to rate on a Likert scale how comfortable they would feel 
answering items on the following screening measures currently used to assess alcohol 
consumption: CAGE, T-ACE and TWEAK. On each of these scales, scores will range from 0 (least 
comfortable) to 5 (most comfortable). The CAGE is a 4-item tool (see Appendix 4) used to screen 
for alcohol dependence difficulties. Participants are required to give a “yes” or “no” response, and a 
score of 2 or more indicates probable alcohol dependence (Ewing, 1984). Studies have illustrated 
its reliability and validity in clinical populations (Liskow et al., 1995), however this measure has 
not been supported for use in the general population. For example Bisson et al. (1999) found the 
CAGE to have poor criterion validity as it was unable to discriminate between heavy drinkers and 
non-drinkers in the general population. SIGN guidelines recommend this measure in primary care 
alongside two qualitative questions on consumption (SIGN, 2003), and has suggested this takes 
approximately 5 minutes to complete.  
 
The T-ACE is 4 item screening tool based on the CAGE, but has been adapted to assess PAU and 
to identify individuals engaging in risky drinking behaviours during pregnancy (see appendix 4). 
Scores on the T-ACE range from 0-5, with a total score of 2 or more indicating greater risks to the 
developing foetus. Studies have also found this screen to be ineffective in identifying risky or 
hazardous drinking behaviours in women (Chang et al., 2010).  The TWEAK is also a validated 
measure used to identify risky drinking behaviours in the pregnant population. Both the TWEAK 
and the T-ACE have been found to have very high specificity rates (99% & 93%, respectively), but 
poor sensitivity (46-43% and 19-34%, respectively) (Sarkar et al., 2010). SIGN guidelines 
recommend use of both of these in obstetric settings such as antenatal and preconception 
consultations (SIGN, 2003).  
 
Following this, participants will be asked to answer questions relevant to their own pregnancy. 
PAU will be assessed using an adapted version of a measure from recent FASD guidelines (SIGN, 
2019) (see Appendix 4). They will also be asked about consumption of other substances which may 
interfere with prenatal development, including nicotine, prescription and non-prescription drugs, 
heroin and cocaine. To assess quantity and frequency of alcohol use, the Alcohol Use Disorder 
Identification Test- Consumption (AUDIT-C) will be utilised (Bush et al., 1998). This self-
administered measure is a 3-item alcohol screen recommended for use by SIGN guidelines (see 
 122 
Appendix 4). Scores range from 0-12, with scores of 1-4 indicating confirmed prenatal alcohol 
exposure to the foetus, and scores of 5 or greater indicating high risk of exposure. It has been 
shown to have good validity and efficiency in identifying risky alcohol use and dependency in a 
diverse range of health and community contexts (de Meneses-Gaya et a., 2009). More specifically, 
it has been demonstrated as a valid and effective screening tool for hazardous drinking and alcohol 
dependence in females with appropriate levels of sensitivity and specificity (0.81 and 0.86, 
respectively) (Bradley et al., 2003). Alcohol unit references will be provided in picture format 
beside these questions as to inform participants of the units in standard drinks. It is felt that by 
administering questions in this order, participants may feel more comfortable reporting alcohol use 
more transparently. 
 
There will a text box provided at the end of the study should participants wish to include any 
further information or thoughts they have regarding the questions in the study.  
 
Section 4: Sample Size 
4.1 What sample size is needed for the research and how did you determine this? 
For quantitative projects, outline the relevant Power calculations and the rationale for assuming 
given effect sizes. For qualitative projects, outline your reasoning for assuming that this sample 
size will be sufficient to address the study’s aims 
IRAS A59 and IRAS A60 
 
As there is limited research in this area, multiple methods were employed to estimate the sample 
size required for sufficient power. G*Power, an online power analysis program for statistical tests 
was utilised initially (Faul et al., 2009). In order to test the principle research question, an a priori 
analysis using a linear multiple regression fixed model with a single regression co-efficient was 
input. A two tailed approach with a medium effect size (f2 = 0.15) and alpha level of 0.05 indicated 
that for 7 predictor variables, a sample size of 89 would be required.  
 
A commonly used “rule of thumb” was also used to estimate sufficient power. Researchers have 
recommended a 10:1 ratio of cases to predictors (Peduzzi et al., 1996). In this study there are the 7 
predictor variables of interest, indicating that 70 participants are needed. However, these 
recommendations vary, and Green (1991) suggests a minimum sample size of 104 is needed plus 
the numbers of predictors (7), which would equate to 111 (VanVoorhis et al., 2007). Additionally, 
similar studies which have investigated the prevalence of alcohol use in pregnant women have had 
larger sample sizes. For example, Smith et al (2014) recruited 409 women from antenatal clinics in 
the South West of England using an anonymous questionnaire. Participants were given hard copies 
of the questionnaire to compete and return via an envelope in the post. 
 
For analyses of secondary research questions, independent sample t tests will be conducted. 
G*Power analysis indicates that in order to achieve statistical power, with a two tailed approach, an 
alpha level 0.05 and large effect size of .5, a sample size of 210 is required. This equates to 105 
women who were pregnant before April 1st 2016, and 105 women who have been pregnant after 
this date.  
 
Recruitment will take place across multiple sites and platforms and so although approximately 200 
participants are required for statistical analyses, the study hopes to recruit more than this. Studies 
which typically employ methodology similar to this study have had large numbers. For example, 
Nilsen et al. (2008) conducted a study assessing women’s alcohol consumption during pregnancy 
through mailed anonymous questionnaires. They had a response rate of 61% and recruited a sample 
size of 869 women over the period of one year.  
 
4.2 Outline reasons for your confidence in being able to achieve a sample of at least this size 
E.g. give details of size of known available sample(s), percentage of this type of sample that 
typically participate in such studies, opinions of relevant individuals working in that area 
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According to National Statistics, the birth rate in Scotland has remained at approximately 54,000 
per year over the past few years (Scottish Government, 2017). Maternity services exist across all 14 
NHS Boards, as well as local third sector organisations such as Maternal Mental Health Scotland, 
Homestart, National Childbirth Trust & Netmums. In the trainee’s health board there is one 
maternity unit in the catchment area which recorded 3350 live births from April 2016-2017. High 
rates of pregnancy in the health board and across Scotland will allow the study to recruit from 
multiple settings such as GP clinical waiting areas and third sector organisations. Leaflets for the 
study will be distributed amongst these as well as in the 2 antenatal centres in the health board.  
 
Online survey research has many advantages including better access to participants that are usually 
difficult to reach, as well as being time efficient and cost-effective. It enables the trainee to 
overcome some of the barriers associated with in-person recruitment, particularly due to the 
sensitive nature of this study. By anonymising the data it is hoped that individuals feels 
comfortable to report more transparently their level of alcohol use and perceptions of current 
screening measures. Additionally, the use of Internet broadens the range of potential participants. 
Scottish health survey indicated that 83.4% of adults in Scotland used the internet for personal use 
in 2016, with 65% using it for social media purposes (Scottish Government, 2017). Studies have 
found that social media platforms such as Facebook have recruited samples representative of the 
population (Nelson et al., 2014) and have enabled recruitment in difficult to reach populations 
(Ramo & Prochaska, 2012). Furthermore, Ibarra et al. (2018) conducted a study examining the 
feasibility of using online platforms to recruit a difficult to reach population, women who smoke 
during pregnancy. Findings revealed that the Qualtrics platform had a recruitment rate of 84%, 
illustrating its efficiency in studies similar to the one proposed here.  
 
These methods of recruitment hope to provide a wide access to large numbers of potential 
participants and the sample size is expected to be larger than the size required for statistical power. 
Furthermore, the study has proposed a recruitment time of 10 months. Other services which can be 
targeted outside of the Health board are online platforms such as Mumsnet, Facebook, twitter, and 
organisations such as Alcohol Focus Scotland, Scottish Drug Forum, Addaction and Phoenix 
Futures. It is hoped that by targeting services for individuals with drug and alcohol use difficulties 
there will be more of a diverse sample of participants with differing levels of alcohol consumption 
during pregnancy. 
 
Section 5: Analysis 
5.1 Describe the methods of analysis (statistical or other appropriate methods, e.g. for 
qualitative methods) by which the data will be evaluated to meet the study objectives 
IRAS A62 
 
Responses will be recorded using the Qualtrics survey platform, and subsequently the data will be 
transferred to IBM SPSS 24 for coding and analysis. The study intends to conduct statistical 
modelling techniqes such as regression analysis to investigate the relationship between independent 
variables such as the demographic factors, on the dependent variable, level of alcohol use during 
pregnancy. In order to answer the primary research question, analyses will explore the relationship 
between socio-economic status and level of reported alcohol use, as well as other factors which 
predict higher levels of alcohol use.  Multiple linear regression analyses will be conducted to make 
predictions and identify significant relationships between the dependent variable and independent 
variables. This will be on the basis that the data meets numerous assumptions including a linear 
relationship between independent and dependent variables, little or no multicollinearity, 
homoscedasticity, multivariate normality and no auto-correlation (Osborne et al., 2002).  
 
Independent sample t tests will be conducted to answer secondary research questions. This will 
compare the means of reported alcohol use in females who were pregnant before and after 
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guidelines on recommended alcohol use during pregnancy had changed (pre and post April 1st 
2016).  
 
Analysis of participants’ attitudes to current alcohol screening instruments will be investigated 
using Likert scales. Analysis will be more of an exploratory approach rather than hypothesis testing 
and will be used to guide interpretation of results. Data on each of the scales will be coded from 1 
(least comfortable) to 5 (most comfortable). A descriptive analysis will be completed for these as 
well as for a free text box which will be added at the end of the survey. This text box will allow 
participants to comment on their thoughts about the survey as a whole. Depending on the uptake 
and content of this, the trainee may analyse this information using a qualitative method; thematic 
analysis. This information will be used in the discussion section to further aid in the interpretation 
of results and make recommendation for future research.  
 
Section 6: Project Management / Timetable 
6.1 Outline a timetable for completion of key stages of the project 
E.g. ethics submission, start and end of data collection, data analysis, completion of systematic review 
 
Project Management Gannt Chart  




































 X             
Ethics 
submission  
  X            
Study 
Preparation 
 X X X           
Systematic 
review 
   X X X X X X      
Data 
collection 
    X X X X X      
Data analysis          X X     
Thesis write 
up 
      X X X X X    
Submit draft 
to supervisor 
          X X   
Final 
corrections 
           X   
Thesis 
submission 
            X  
Viva             X  
Dissemination              X 
 
 
Section 7: Management of Risks to Project 
7.1 Summarise the main potential risks to your study, the perceived likelihood of occurrence 
of these risks and any steps you will or have taken to reduce these risks. Outline how you will 
respond to identified risks if they should occur 
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Failure to receive ethical approval  
This study may fail to receive ethical approval due to concerns raised regarding the possibility of 
adverse outcomes to individuals who partake in the study. As discussed in section 1, disclosure of 
alcohol use during pregnancy can result in the person feeling guilty or blamed. The perceived 
likelihood of this risk is low however, as there appears to be no research to suggest that asking 
questions on alcohol use during pregnancy causes significant harm, and alcohol screening 
instruments are used routinely in practice (Chang, 2001).   
 
Participants will be directed to an information sheet before commencing the study and will be 
informed of the sensitive nature of the study. In the event that participants may become 
psychologically distressed, they will be directed at the beginning and end of the study to helplines 
and services they can access for support.  
 
Issues with recruitment 
Alike other studies, a major risk is that the study fails to recruit a sufficient number of participants 
and that the study may be underpowered. In order to mitigate the risks of this, recruitment will take 
place across several settings (as detailed in section 3.4). Third sector organisations and use of social 
media platforms should further reduce the possibility that the study will recruit insufficient 
numbers. Additionally, this study is predicted to have approximately 10 months for data collection, 
allowing for further organisations and services to be targeted across health boards if required.  
 
Stigma associated with alcohol use is a further potential risk for lack of recruitment. Participants 
may not wish to disclose their level of alcohol use during pregnancy or may under-report this, 
which may result in a skewed participant pool. Furthermore, the study’s sample will be self-
selecting and so bias is likely. 
Studies have shown that women are likely to underreport consumption or deny alcohol use out of 
embarrassment (Morrow-Tlucak et al, 1989). The study aims to mitigate this risk by anonymity, 
and participants are not obliged to disclose this information should they wish not to.  
 
Studies utilising population surveys have indicated other factors associated with under-reporting, 
including memory difficulties due to high levels of alcohol consumption, the manner in which 
questions are constructed, and high non-participation rates in samples with high levels of use 
(Sobell & Sobell, 1995).  In order to address some of these concerns, this study aims to construct 
objective questions and target populations where there is likely to be higher numbers of alcohol or 
substance use problems. Participants will be identified from these groups by answering an item 
asking how they had come across the study. 
 
Length of battery 
The study is estimated to take 15 minutes. All individuals will be directed to an information sheet 
and consent form upon signing up for the study, and a debriefing form at the end. It is possible that 
attrition will occur during the study as individual’s choose not to complete all items. The study 
aims to recruit larger numbers than needed for a sufficient sample size to account for this 
possibility and reduce the impact of this on overall sample size analysis. 
 
Data storage 
All data will be entered via an online platform and will be stored anonymously and securely within 
the University of Edinburgh database (see Section 3.1). The perceived risks around data storage 
and loss of data is relatively low.  
 
Section 8: Knowledge Exchange 




The proposed study and its hypotheses will be pre-registered on the Open Science Framework 
before data collection and will be accessible online via the Open registries Network 
(https://osf.io/registries). This hopes to promote transparency and quality, improve the credibility of 
the research findings, and reduce ‘hindsight bias’ whereby data is used to generate a post-diction or 
explanation of results (Noseck et al., 2019). It will be written up in a portfolio format which will 
include a systematic review of the literature, and the results of the empirical research project 
conducted. It will be submitted as a Clinical Psychology Doctorate Thesis to the University of 
Edinburgh and subsequently uploaded to the Edinburgh Research Archives database which is freely 
accessible online. 
 
It will be prepared for submission to an academic journal such as the UK Journal of Public Health 
which has an impact factor of 1.7. Other studies investigating PAU and healthcare professional 
attitudes have published in similar journals in order to target the most appropriate population 
(Payne et al., 2005) (Zicco & Racine, 2017). The trainee also plans to present the research at a 
departmental conference within their health board and seek opportunities at other relevant events 
such as local conferences, CPD events and poster sessions. As the Scottish Government has 
recommended further research to be conducted in this area, results will be cascaded to members of 
the committee who will be actively involved in the design of this research project, and further 
disseminated to health care professionals such as GP’s and midwives in order to help inform 
practice.  
 
 In order to disseminate the study to a wider audience and the general population who may have 
participated in the study, this article will be shared on social media platforms such as Twitter, 
Linkedin and Facebook. A lay summary of the research will be posted on forums such as Mumsnet 
and Alcohol Focus Scotland with permission, to reach individuals who may not have participated in 
the study and further raise awareness of alcohol use during pregnancy.  
 
8.2 What are the anticipated benefits or implications of the project? 
E.g. if this is an NHS project, in what way(s) is the project intended to benefit the NHS? 
 
This study aims to gain a more transparent perspective on the prevalence of alcohol consumption 
during pregnancy in Scotland. Existing prevalence data is under representative of the general 
population and does not correspond with alcohol sales (Scottish Health Survey, 2015) (Sharp et al., 
2014). Despite increased awareness and acknowledgment of the risks associated with PAU, rates of 
consumption remain high at 41%. Guidelines for recommended PAU have changed, and there 
appears to be no research conducted on level of education surrounding this since. This study aims 
to address this gap in the literature, as well as exploring other factors associated with alcohol use 
during pregnancy, such as sociodemographic factors and history of mental health difficulties.  
 
The Scottish Government has recently highlighted the need for further research in the area of PAU 
and FASD. SIGN guidelines recommend work in diagnoses and early intervention for FASD. As 
PAU is a direct cause of FAS and FASD, it is important to understand how information on alcohol 
consumption can be elicited in a more transparent, less stigmatised manner. This information is 
crucial in identifying children who have been prenatally exposed to alcohol, but which is not 
reported in their medical records.  
 
This study has the potential to improve likelihood of diagnoses of FASD in this population by 
highlighting a more realistic prevalence of PAU in Scotland and exploring the most appropriate 
ways in which this can be assessed. At present there is minimal published research on factors 
relating to underreporting of alcohol consumption and this aims to add to the literature base in 
providing a better understanding of this. It hopes to inform recommendations for healthcare 
providers about how best to screen for alcohol consumption in pregnant women and better predict 
risks of FASD. This study also aims to indirectly improve patient’s engagement with health 
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services and improve quality and transparency of care through recommendations made from the 
findings. 
 
8.3 Are the any potential costs for the project? 
Outline any potential financial costs to the project, including the justification for the costs (why are 
these necessary for the research project?) and how funding will be obtained for these costs (how 
will they be met?) Please separate these into potential costs for the University and potential costs 
for your NHS Board and note that you should ask your NHS Board to meet stationery, printing, 
postage and travel costs. 
 
University of Edinburgh 
 
There are no foreseen costs for the University of Edinburgh as measures are freely available, and 




Minimal costs are anticipated for the NHS health board. Leaflets for the study will be printed and 
distributed across several sites. This may incur some travel costs however this is expected to be 
minimal due to the geography of the health board and of centres located nearby the trainee’s base. 
There will be some postage costs for the distribution of leaflets to third sector organisations. It is 
also anticipated that there will be printing costs for a research poster to be used as part of the 
study’s dissemination. Funding for these materials will be applied for once ethical approval has 
been sought.  
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Section 11: Confirmation of Supervisors’ Approval 
“I confirm that both my Academic and Clinical Supervisors have seen and approved this 
research proposal and have both completed the supervisors’ appraisal forms below.” 











Do you consider that the project should proceed in broadly its current form? 
Delete as appropriate 
Yes   
 
Outline the reasons for the above response 
Highlight any areas of risk to the completion of the project that have not been fully addressed 
within the proposal and any steps that could be taken to reduce risks 
I am pleased that Orlagh has chosen to pursue a study in what is an area of current concern for the 
Scottish Government and  which addresses an importance healthcare issue.  Despite significant 
efforts by Orlagh to identify a project that would include the neuropsychological assessment of 
affected children extensive consultation with her healthboard have indicated that this will not be 
possible.  Instead Orlagh has devised this attached study as a means to make an important 
contribution to this area in the absence of such assessments. 
 
I believe that the study is feasible and would value the opinion of the marker on whether they 










Do you consider that the project should proceed in broadly its current form? 
Delete as appropriate 
Yes   
 
Outline the reasons for the above response 
Highlight any areas of risk to the completion of the project that have not been fully addressed 
within the proposal and any steps that could be taken to reduce risks 
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I think the online nature of the questionnaire means we would be successful in recruitment, and the 
ability to skip questions or drop out will ensure participants feel comfortable in answering as 
required, as well as giving us valuable information about the questions used in clinical practice. 
The debriefing sheet will ensure participants are directed to suitable support should the 





Appendix D: Participant Information Sheet  
 
 
Research study: Pregnancy, Alcohol and Behaviour: The impact of an information leaflet 
on women’s attitudes towards drinking during pregnancy  
 
 
Thank you for following the link to this study. We are very pleased to invite you to take 
part. Please read this Participant Information Page before you decided whether or not you wish to 
take part.  
 
What is the purpose of the study? 
As part of an education programme this study explores women’s knowledge, use and attitudes 
towards drinking during pregnancy. We want to find out if these factors influence how much women 
drink while they are pregnant. We are also interested in the effect of an information leaflet on 
women’s attitudes.  We hope that by better understanding alcohol use during pregnancy we will be 
able to provide better support for women during their pregnancy.  
 
Who can take part? 
Women who are: 
o at least 18 years old; 
o currently, or have been pregnant at any point since April 1st 2016  
o able to read and write to a secondary school level.  
Those who are below the age of 18, who have not been pregnant since April 2016, or those whom 
have additional support needs will be excluded from taking part in the study.  
What will the survey ask? 
o It will direct you first to a consent page where you will be asked to provide your consent 
should you wish to participate in the study 
o The survey will then ask: some information about yourself e.g. age, ethnicity, marital status, 
level of education, employment status and general questions about your most recent 
pregnancy.  
o Some general questions about your behaviour e.g. how you react when good things happen to you 
o Your alcohol use before and after you found out that you were pregnant  
o Your beliefs and attitudes towards drinking during pregnancy  
 
We’ll then ask you to read an information leaflet on drinking in pregnancy before asking you a small 
number of questions to measure if the leaflet has changed your attitudes. Completing the survey will 
take approximately 20 minutes.  
 
Do I have to take part? No, it’s up to you whether you would like to take part. Participation is 
voluntary and you can withdraw at any time, without giving a reason and without adverse 
consequences or academic penalty, by closing the browser window. As your participation is 
anonymous, it will not be possible to remove your data. Once you start the survey you will have 1 
week to complete it. If you do not complete it within this time the survey will automatically close 
and your data will be recorded as a partial response.  
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Are there any benefits? This study hopes to reduce the stigma associated with alcohol use during 
pregnancy by providing a safe and anonymous space to share your views.  In addition to the 
opportunity to enter our prize draw, your answers will help us better understand alcohol use during 
pregnancy and whether an information leaflet has a positive impact.  
 
As a thank you for your time, at the end of survey you will have the chance to enter a prize draw for 
a chance to win one of three £50 Amazon gift cards. This will direct you towards an anonymous link 
where you can enter an email address to take part.  
 
Are there any disadvantages? 
There are no known risks for you in this study. However, we are aware that the topic of pregnancy 
and alcohol can be regarded as sensitive. We don’t think that our questions will cause any 
discomfort but, we’ve provided details of support services at the end of the study on the debrief 
form and on our web-page. Please take some time to read the information about where to seek 
appropriate support should you feel distressed and remember that you can also exit the survey at 
any time by exiting the browser. 
 
Will my taking part in the study be kept confidential? YES. All of the information collected from the 
survey will be kept confidential and processed in accordance with the Data Protection Law. The 
survey software does not collect information that would allow us to identify any information about 
you.  All information collected will be stored in a single secure data centre which complies with UK 
standards. 
 
If you choose to enter into the prize draw on completion of the study, you will be directed to a 
separate link in order to provide an email address. This email address will be stored separately to 
your responses to the survey in order to ensure that your anonymity is preserved and will be deleted 
once the prize draw has been completed in June 2021.   
 
What will happen to my data? 
The research data collected during the study may be looked at by project researchers from the 
University of Edinburgh. The University of Edinburgh is the sponsor for this study based in the United 
Kingdom. We will be using information from you in order to undertake this study and will act as the 
data controller for this study. This means that we are responsible for looking after your information 
and using it properly. The University of Edinburgh will keep anonymised information about you for a 
minimum of 5 years after the study has finished.  For general information about how we use your 
data go to: https://www.ed.ac.uk/records-management/privacy-notice-research  
 
What will happen when the study is finished? Once the study is completed, the researcher will 
prepare a report which will summarise the findings of the study. You will not be identifiable in any 
report or publication. This report may be published in a scientific journal and/or disseminated to the 
wider research community. Your anonymised data will be stored for a minimum of 5 years and may 
also be used in future ethically-approved studies. You will be able to access a summary of the study’s 
results on our webpage once completed. Please check the following webpage from July 2021 
onwards: (please see link to webpage below). 
 
Who is organising and funding the research?  The study has been sponsored by the University of 
Edinburgh and funded by NHS Education Scotland as part of their support for the East of Scotland 
Clinical Psychology Doctoral Training Programme.    
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Who has reviewed the study?  
This project has been approved by the Ethics Review Committee at School of Health in Social Science 
at the University of Edinburgh. 
 
If you would like further information, please contact the Chief Investigator: Orlagh Keating at 
pregnancy.behaviour@ed.ac.uk 
 
If you wish to discuss the study further with the project’s academic supervisor, please contact: 
Dr Suzanne O’Rourke, University of Edinburgh at Suzanne.O'Rourke@ed.ac.uk   
 
 
If you would like to discuss the project with someone independent of the study, please contact: 
Dr. Angus MacBeth, University of Edinburgh at angus.macbeth@ed.ac.uk 
 
If you would like to make a complaint about the study, please contact: The University of Edinburgh 
Research Governance Team at cahss.res.ethics@ed.ac.uk  
 
 
If reading this has raised any questions or made you feel uncomfortable in any way, you can find 
support from the following services: 
 
• Your GP 
• Your Midwife or Health Visitor  
• NHS 24 (dial 111) 
• Samaritans – confidential listening service (dial 116 123) 
• Breathing Space – confidential listening and signposting to other services (dial 0800 838 587) 
• Maternal Mental Health Scotland – for information and signposting to helpful services 
(maternalmentalhealthscotland.org.uk)  
• Drinkline - National confidential helpline for anyone who is concerned about their drinking, 




You may also want to try the following acts of self-care to help yourself feel more settled: 
 
• Take time out to quietly enjoy a warm drink; 
• Go for a gentle walk; 
• Take a bath; 
• Speak to a friend who makes you feel understood. 
 




Appendix E: Consent form 
 
 
Participant Consent Page (Administered via Qualtrics) 
 
Title of Study: Pregnancy, Alcohol and Behaviour: The impact of an information leaflet on women’s 
attitudes towards drinking during pregnancy 
 
 
Clicking on the "agree" button below indicates that you give your consent to the following:  
 
1. I confirm that I have read and understand the information sheet (version 2 dated 08 
July2020) for the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
2. I am participating voluntarily and understand that I am free to withdraw from the study at 
any time, without giving any reason, and without adverse consequences or academic 
penalty. 
3. I understand that the research data collected during the study may be looked at by project 
researchers from the University of Edinburgh. I agree to give permission for these individuals 
to access my data. 
4. I agree to give permission for my anonymised responses to the survey to be used in the 
researcher's publications on this topic. 
5. I understand that if I wish to enter the prize draw I will be asked to provide an email address 
which will be kept until the winners of the draw have been chosen at the end of the study 
(June 2021). I understand that this email address will not be linked to my survey responses. 
6. I understand that relevant sections of my data collected during the study may be looked at 
by individuals from the Sponsor (University of Edinburgh), where it is relevant to my taking 
part in this research. I give permission for these individuals to have access to my data. 
7. I understand that my anonymised data collected will be retained for a duration of 5 years 
following completion of the study and may be used in future ethically approved research. 
8. I agree to the above consent points and agree to participate in the above research study.  
 
 
If you do not wish to participate, please decline participation by clicking on the "disagree" button or 
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